

(19)  Canadian
Intellectual Property
Office

An Agency of
Industry Canada

Office de la Proprié
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

(11) CA 2 529 729

(13) A1

(40) 23.12.2004
(43) 23.12.2004

(12)

(21) 2 529 729

(51) Int. Cl.:

(22) 11.06.2004

A61K 31/5025 (2006.01)
C07D 221/00 (2006.01)
C07D 235/00 (2006.01)
C07D 471/00 (2006.01)
C07D 487/04 (2006.01)
A61P 3/10 (2006.01)
C07D 231/00 (2006.01)
C07D 237/00 (2006.01)
C07D 471/04 (2006.01)
C07D 498/00 (2006.01)

(85) 16.12.2005

(86) PCT/EP04/006303

(87) WO04/111051

(30) DE 103 27 439.1 DE 18.06.2003

ECKHARDT, MATTHIAS (DE).
KAUFFMANN-HEFNER, IRIS (DE).
TADAYYON, MOHAMMAD (DE).
HAUEL, NORBERT (DE).
HIMMELSBACH, FRANK (DE).
LANGKOPF, ELKE (DE).
MARK, MICHAEL (DE).

(71) BOEHRINGER INGELHEIM INTERNATIONAL
GMBH,
Binger Strasse 173
55216, INGELHEIM AM RHEIN, XX (DE).


(72)

(74)
FETHERSTONHAUGH & CO.

(54) NOUVEAUX DERIVES D'IMIDAZOPYRIDAZINONES ET D'IMIDAZOPYRIDONES, LEURS PREPARATIONS ET
LEUR UTILISATION COMME COMPOSITIONS PHARMACEUTIQUES

(54) NEW IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF
AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS

(57) The invention relates to substituted imidazo-pyridinones and imidazo- pyridazinones of general formula (I), wherein Y and R1 to R4 are defined as indicated in claim 1, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof that have valuable pharmacological properties, especially an inhibiting effect on the activity of the dipeptidyl peptidase IV (DPP-IV) enzyme.





Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2529729 A1 2004/12/23

(21) 2 529 729

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2004/06/11
(87) Date publication PCT/PCT Publication Date: 2004/12/23
(85) Entrée phase nationale/National Entry: 2005/12/16
(86) N° demande PCT/PCT Application No.: EP 2004/006303
(87) N° publication PCT/PCT Publication No.: 2004/111051
(30) Priorité/Priority: 2003/06/18 (DE 103 27 439.1) DE


(51) Cl.Int./Int.Cl. C07D 487/04 (2006.01),
C07D 519/00 (2006.01), C07D 498/00 (2006.01),
A61K 31/5025 (2006.01), C07D 471/04 (2006.01),
C07D 471/00 (2006.01), C07D 237/00 (2006.01),
C07D 235/00 (2006.01), C07D 231/00 (2006.01),
C07D 221/00 (2006.01), A61P 3/10 (2006.01)

(71) Demandeur/Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH,
DE

(72) Inventeurs/Inventors:
ECKHARDT, MATTHIAS, DE;
HAUEL, NORBERT, DE;
LANGKOPF, ELKE, DE;
...

(54) Titre : DERIVES D'IMIDAZOPYRIDAZINONES ET D'IMIDAZOPYRIDONES, LEUR PREPARATION ET LEUR UTILISATION COMME MEDICAMENTS

(54) Title: IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS



(57) Abrégé/Abstract:

The invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula (I), wherein Y and R1 to R4 are defined as indicated in claim 1, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof that have valuable pharmacological properties, especially an inhibiting effect on the activity of the dipeptidyl peptidase IV (DPP-IV) enzyme.

Canada

<http://opic.gc.ca> · Ottawa-Hull K1A 0C9 · <http://cipo.gc.ca>

OPIC · CIPO 191


OPIC CIPO

(72) Inventeurs(suite)/Inventors(continued): HIMMELSBACH, FRANK, DE; KAUFFMANN-HEFNER, IRIS, DE;
TADAYYON, MOHAMMAD, DE; MARK, MICHAEL, DE

(74) Agent: FETHERSTONHAUGH & CO.

Abstract

The present invention relates to substituted imidazo-pyridinones and imidazo-
5 pyridazinones of general formula



wherein Y and R¹ to R⁴ are defined as in claim 1, the tautomers, enantiomers,
10 diastereomers, the mixtures thereof and the salts thereof, which have valuable
pharmacological properties, particularly an inhibiting effect on the activity of the
enzyme dipeptidylpeptidase-IV (DPP-IV).


1

84310fft

New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof
and their use as pharmaceutical compositions

5

The present invention relates to new substituted imidazopyridazinones and imidazopyridones of general formula



10

the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

15

20

The present invention thus relates to the above compounds of general formula I which have valuable pharmacological properties, the pharmaceutical compositions containing the pharmacologically effective compounds, the use thereof and processes for the preparation thereof.

In the above general formula I

R^1 denotes a C_{1-3} -alkyl group substituted by a group R_a , where

R_a denotes a 3,4-dihydro-quinolinyl, 3,4-dihydro-isoquinolinyl, 1,4-dihydro-quinazolinyl, 3,4-dihydro-quinazolinyl, 1*H*-benzo[*d*][1,2]oxazinyl, 4*H*-benzo[*e*][1,3]oxazinyl, 4*H*-benzo[*d*][1,3]oxazinyl or 2*H*-benzo[1,4]oxazinyl group, wherein in each case

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group,

10 a 4*H*-benzo[*e*][1,3]thiazinyl, 4*H*-benzo[*d*][1,3]thiazinyl or 2*H*-benzo [1,4]thiazinyl group wherein in each case

15 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group,

20 a 2-oxo-2*H*-benzo[*e*][1,3]oxazinyl or 2,2-dioxo-1*H*-benzo[*c*][1,2]thiazinyl group wherein in each case in the benzo moiety

one to three methyne groups may each be replaced by a nitrogen atom,

25 a 2,3-dihydro-1*H*-benzo[*e*][1,4]diazepinyl, 4,5-dihydro-3*H*-benzo[*b*][1,4]diazepinyl or 5-oxo-4,5-dihydro-3*H*-benzo[*e*][1,4]diazepinyl group wherein in each case

30 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocyclyl moiety a methylene group may be replaced by a carbonyl group,

a 2,3-dihydro-benzo[*f*][1,4]oxazepinyl or 2,3-dihydro-benzo[*b*][1,4]oxazepinyl group wherein in each case

3

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group,

5 a 2,3-dihydro-benzo[*b*][1,4]thiazepinyl or 2,3-dihydro-benzo[*f*][1,4]thiazepinyl group wherein in each case

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group,

10

a 5-oxo-4,5-dihydro-benzo[*f*][1,3,4]oxadiazepinyl group wherein

15

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom,

20

a 11*H*-dibenzo[*b,e*]azepinyl or 5*H*-dibenzo[*a,d*]cycloheptenyl group wherein in each case

25

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and the methylene group in the heterocycll moiety may be replaced by an oxygen or sulphur atom, a carbonyl, sulphinyl or sulphonyl group or by an imino group substituted by R_x, where

30

R_x denotes a hydrogen atom or a C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkynyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkyl, aryl, aryl-C₁₋₃-alkyl, hydroxy-C₂₋₄-alkyl, C₁₋₃-alkyloxy-C₂₋₄-alkyl, C₃₋₆-cycloalkyloxy-C₂₋₄-alkyl, amino-C₂₋₄-alkyl, C₁₋₃-alkylamino-C₂₋₄-alkyl, di-(C₁₋₃-alkyl)-amino-C₂₋₄-alkyl, C₁₋₃-alkyl-carbonyl, C₁₋₃-alkyloxy-carbonyl, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyl, aryl-carbonyl,

C₁₋₃-alkyl-sulphonyl or aryl-sulphonyl group,

a phenanthridinyl group wherein

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, and

5 a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenanthridinyl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphthyl or a 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphthyl group wherein in each case

10 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and one or two methylene groups may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units,

15 a phenanthrenyl group wherein

in each case one to three of the methyne groups in position 1 to 4 and 5 to 8 may each be replaced by a nitrogen atom,

20 a 1,2,3,4-tetrahydro-phenanthrenyl or a 1,2,3,4,5,6,7,8-octahydro-phenanthrenyl group wherein

25 in each case one or two of the methylene groups in position 1 to 4 and 5 to 8 may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units,

30 a 5*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepinyl, thieno[3,2-*b*][1,4]benzoxazepinyl, 5*H*-dibenzo[*d,f*][1,3]diazepinyl or a 5-oxa-7-aza-dibenzo[*a,c*]cycloheptenyl group wherein in each case

5

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom,

5 a naphtho[1,2-d]oxazolyl, naphtho[2,1-d]oxazolyl, naphtho[1,2-d]thiazolyl, naphtho[2,1-d]thiazolyl, naphtho[1,2-d]imidazolyl, naphtho[1,2-b]furanyl or naphtho[2,1-b]furanyl group wherein in each case

in the naphthyl moiety one to three methyne groups may each be replaced by a nitrogen atom,

10 or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1*H*-perimidinyl group,
15 while the methylene and methyne groups of the above mentioned radicals R_a may be substituted by the groups R¹⁰ to R¹³ and additionally by a C₁₋₃-alkyl group and the imino groups of the above mentioned radicals R_a may be substituted by the groups R_x as hereinbefore defined and

R¹⁰ denotes a hydrogen atom,

20 a fluorine, chlorine, bromine or iodine atom,

a C₁₋₄-alkyl, hydroxy, or C₁₋₄-alkyloxy group,

25 a nitro, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)amino, cyano-C₁₋₃-alkylamino, N-(cyano-C₁₋₃-alkyl)-N-(C₁₋₃-alkyl)-amino, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, or 4-(C₁₋₃-alkyl)-piperazin-1-yl group,

30 a C₁₋₃-alkyl-carbonylamino, arylcarbonylamino, aryl-C₁₋₃-alkyl-carbonylamino, C₁₋₃-alkyloxy-carbonylamino, aminocarbonylamino, C₁₋₃-alkylaminocarbonylamino, di-(C₁₋₃-alkyl)aminocarbonylamino, pyrrolidin-1-yl-carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino or 4-(C₁₋₃-alkyl)-piperazin-

- 6
- 1-yl-carbonylamino, C₁₋₃-alkyl-sulphonylamino, bis-(C₁₋₃-alkylsulphonyl)-amino, aminosulphonylamino, C₁₋₃-alkylamino-sulphonylamino, di-(C₁₋₃-alkyl)amino-sulphonylamino, pyrrolidin-1-yl-sulphonylamino, piperidin-1-yl-sulphonylamino, morpholin-4-yl-sulphonylamino, piperazin-1-yl-sulphonylamino or 4-(C₁₋₃-alkyl)-piperazin-1-yl-sulphonylamino, (C₁₋₃-alkylamino)thiocarbonylamino, (C₁₋₃-alkyloxy-carbonyl-amino)carbonylamino, arylsulphonylamino or aryl-C₁₋₃-alkyl-sulphonyl-amino group,
- 5
- an N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-arylcarbonyl-amino, N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyloxy-carbonylamino, N-(aminocarbonyl)-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl-aminocarbonyl)-C₁₋₃-alkylamino , N-[di-(C₁₋₃-alkyl)aminocarbonyl]-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-sulphonylamino, N-(C₁₋₃-alkyl)-arylsulphonylamino, or N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-sulphonylamino group,
- 10
- a 2-oxo-imidazolidin-1-yl, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1-yl or 2-oxo-hexahdropyrimidin-1-yl group wherein the nitrogen atom in the 3 position may be substituted in each case by a methyl or ethyl group,
- 15
- a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkyl-aminocarbonyl, di-(C₁₋₃-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl group,
- 20
- a C₁₋₃-alkyl-carbonyl or an arylcarbonyl group,
- 25
- a carboxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyl, cyano-C₁₋₃-alkyl, aminocarbonyl-C₁₋₃-alkyl, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyl, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyl, piperidin-1-yl-carbonyl-C₁₋₃-alkyl, morpholin-4-yl-carbonyl-C₁₋₃-alkyl,
- 30

7

piperazin-1-yl-carbonyl-C₁₋₃-alkyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyl group,

5 a carboxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyloxy, cyano-C₁₋₃-alkyloxy, aminocarbonyl-C₁₋₃-alkyloxy, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyloxy, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyloxy, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyloxy, piperidin-1-yl-carbonyl-C₁₋₃-alkyloxy, morpholin-4-yl-carbonyl-C₁₋₃-alkyloxy, piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy group,

10 a hydroxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl, pyrrolidin-1-yl-C₁₋₃-alkyl, piperidin-1-yl-C₁₋₃-alkyl, morpholin-4-yl-C₁₋₃-alkyl, piperazin-1-yl-C₁₋₃-alkyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyl group,

15 a hydroxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphonyl-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphinyll-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphonyl-C₁₋₃-alkyloxy, amino-C₁₋₃-alkyloxy, C₁₋₃-alkylamino-C₁₋₃-alkyloxy, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyloxy, pyrrolidin-1-yl-C₁₋₃-alkyloxy, piperidin-1-yl-C₁₋₃-alkyloxy, morpholin-4-yl-C₁₋₃-alkyloxy, piperazin-1-yl-C₁₋₃-alkyloxy or 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyloxy group,

20 25 a mercapto, C₁₋₃-alkylsulphonyl, C₁₋₃-alkylsulphinyll, C₁₋₃-alkylsulphonyl, C₁₋₃-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphonyl, trifluoromethylsulphinyll or trifluoromethylsulphonyl group,

30 a sulpho, aminosulphonyl, C₁₋₃-alkyl-aminosulphonyl, di-(C₁₋₃-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-sulphonyl group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms,

an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,

a C₂₋₄-alkenyl or C₂₋₄-alkynyl group,

5 a C₃₋₄-alkenyloxy or C₃₋₄-alkynyloxy group,

a C₃₋₆-cycloalkyl or C₃₋₆-cycloalkyloxy group,

10 a C₃₋₆-cycloalkyl-C₁₋₃-alkyl or C₃₋₆-cycloalkyl-C₁₋₃-alkyloxy group or

an aryl, aryloxy, aryl-C₁₋₃-alkyl or aryl-C₁₋₃-alkyloxy group,

15 R¹¹ and R¹², which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C₁₋₃-alkyl, trifluoromethyl, hydroxy, C₁₋₃-alkyloxy or cyano group, or

R¹¹ together with R¹², if these are bound to adjacent carbon atoms, also denotes a methylenedioxy, difluoromethylenedioxy, ethylenedioxy or a straight-chain C₃₋₅-alkylene group and

20 R¹³ denotes a hydrogen atom, a fluorine, chlorine or bromine atom, a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkyloxy group,

R² denotes a hydrogen, fluorine or chlorine atom,

25 a C₁₋₆-alkyl group,

a C₂₋₄-alkenyl group,

a C₃₋₄-alkynyl group,

30 a C₃₋₆-cycloalkyl group,

a C₃₋₆-cycloalkyl-C₁₋₃-alkyl group,

⁹

a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydro-furanyl methyl or tetrahydropyranyl methyl group,

an aryl group,

5

an aryl-C₁₋₄-alkyl group,

an aryl-C₂₋₃-alkenyl group,

10 an arylcarbonyl group,

an arylcarbonyl-C₁₋₂-alkyl group,

a heteroaryl group,

15

a heteroaryl-C₁₋₃-alkyl group,

a furanylcarbonyl, thienylcarbonyl, thiazolylcarbonyl or pyridylcarbonyl group,

20 a furanylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group,

a C₁₋₄-alkyl-carbonyl group,

25 a C₁₋₄-alkyl-carbonyl-C₁₋₂-alkyl group,

a C₃₋₆-cycloalkyl-carbonyl group,

a C₃₋₆-cycloalkyl-carbonyl-C₁₋₂-alkyl group,

30

an aryl-A or aryl-A-C₁₋₃-alkyl group, where A denotes an oxygen or sulphur atom, an imino, C₁₋₃-alkylimino, sulphinyl or sulphonyl group,

a group R_b, where

10

- R_b denotes a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkylamino-carbonyl, di-(C₁₋₃-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-ethylpiperazin-1-ylcarbonyl, hydroxy, mercapto, C₁₋₃-alkyloxy, C₁₋₃-alkylsulphenyl, C₁₋₃-alkylsulphinyll, C₁₋₃-alkylsulphonyl, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group,
- 10 or a C₁₋₄-alkyl group substituted by a group R_b, where R_b is as hereinbefore defined,
- Y denotes a nitrogen atom or a group of formula C-R⁵,
- 15 while R⁵ is defined like R² and in each case one of the two groups R² and R⁵ must be a hydrogen atom or a C₁₋₃-alkyl group,
- R³ denotes a C₃₋₈-alkyl group,
- 20 a C₁₋₃-alkyl group substituted by a group R_c, where
- R_c denotes a C₃₋₇-cycloalkyl group optionally substituted by one or two C₁₋₃-alkyl groups,
- 25 a C₅₋₇-cycloalkenyl group optionally substituted by one or two C₁₋₃-alkyl groups,
- an aryl group or
- 30 a furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl group, while the above mentioned heterocyclic groups may each be substituted by one or two C₁₋₃-alkyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, cyano or C₁₋₃-alkyloxy group,

a C₃₋₈-alkenyl group,

a C₃₋₆-alkenyl group substituted by a fluorine, chlorine or bromine atom or by a

5 trifluoromethyl group,

a C₃₋₈-alkynyl group,

an aryl group or

10

an aryl-C₂₋₄-alkenyl group,

and

15 R⁴ denotes an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C₁₋₃-alkylamino or a di-(C₁₋₃-alkyl)amino group and may additionally be substituted by one or two C₁₋₃-alkyl groups,

a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position

20 or in the 4 position by an amino, C₁₋₃-alkylamino or a di-(C₁₋₃-alkyl)amino group and may additionally be substituted by one or two C₁₋₃-alkyl groups,

a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety is additionally substituted by an aminocarbonyl, C₁₋₂-alkyl-aminocarbonyl, di-(C₁₋₂-

25 alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl-)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group,

a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety in the 4 position or in

30 the 5 position is additionally substituted by a hydroxy or methoxy group,

a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group,

12

a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino- group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl-group are replaced by a straight-chain alkylene bridge, this bridge containing 2 to 5

- 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or 1 to 4 carbon atoms, if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms, if the hydrogen atoms are located on carbon atoms which are separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms,

10

an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl group,

15

a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C₁₋₃-alkyl groups,

a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C₁₋₃-alkyl groups,

20

a [1,4]diazepan-1-yl group optionally substituted by one or two C₁₋₃-alkyl groups, which is substituted in the 6 position by an amino group,

a C₃₋₇-cycloalkyl group which is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-

- 25 alkyl)-amino group,

a C₃₋₇-cycloalkyl group which is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

30

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms,

5

an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms,

10

a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

15 an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

20

an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

25 a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

30 an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

a R¹⁹-C₂₋₄-alkylamino group wherein R¹⁹ is separated from the nitrogen atom of the C₂₋₄-alkylamino moiety by at least two carbon atoms and

14

R¹⁹ denotes an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

an R¹⁹-C₂₋₄-alkylamino group wherein the nitrogen atom of the C₂₋₄-alkylamino moiety is substituted by a C₁₋₃-alkyl group and R¹⁹ is separated from the nitrogen atom of the

5 C₂₋₄-alkylamino moiety by at least two carbon atoms, while R¹⁹ is as hereinbefore defined,

an amino group substituted by the group R²⁰ wherein

10 R²⁰ denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-ylmethyl group, while the groups mentioned for R²⁰ may each be substituted by one or two C₁₋₃-alkyl groups,

15 an amino group substituted by the group R²⁰ and a C₁₋₃-alkyl group wherein R²⁰ is as hereinbefore defined, while the groups mentioned for R²⁰ may each be substituted by one or two C₁₋₃-alkyl groups,

20 an R¹⁹-C₃₋₄-alkyl group wherein the C₃₋₄-alkyl moiety is straight-chained and may additionally be substituted by one or two C₁₋₃-alkyl groups, while R¹⁹ is as hereinbefore defined,

a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group,

25 a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group,

30 or an azetidin-2-yl-C₁₋₂-alkyl, azetidin-3-yl-C₁₋₂-alkyl, pyrrolidin-2-yl-C₁₋₂-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C₁₋₂-alkyl, piperidin-2-yl-C₁₋₂-alkyl, piperidin-3-yl, piperidin-3-yl-C₁₋₂-alkyl, piperidin-4-yl or piperidin-4-yl-C₁₋₂-alkyl group, while the above mentioned groups may each be substituted by one or two C₁₋₃-alkyl groups,

15

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be mono- or disubstituted by R_h, while the substituents may be identical or different and R_h denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl,

5 aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C₁₋₃-alkyl, cyclopropyl, ethenyl, ethynyl, hydroxy, C₁₋₃-alkyloxy, difluoromethoxy or trifluoromethoxy group,

by the heteroaryl groups mentioned in the definition of the above groups are meant a
10 pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group,

or a pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two methyne groups are replaced by nitrogen atoms,

15 or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group, wherein one to three methyne groups are replaced by nitrogen atoms,

and the above mentioned heteroaryl groups may be mono- or disubstituted by
20 R_h, while the substituents may be identical or different and R_h is as hereinbefore defined,

while, unless otherwise stated, the above mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched,

25 and the hydrogen atoms of the methyl or ethyl groups contained in the definitions may be wholly or partly replaced by fluorine atoms,

the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs
30 thereof and the salts thereof.

Compounds of the above general formula I which contain one or more groups that can be cleaved *in vivo* are so-called prodrugs.

16

The carboxy groups mentioned in the definition of the above mentioned groups may be replaced by a group which can be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions,

- 5 and furthermore the amino and imino groups mentioned in the definition of the above mentioned groups may be substituted by a group which can be cleaved *in vivo*. Such groups are described for example in WO 98/46576 and by N.M. Nielsen *et al.* in International Journal of Pharmaceutics 39, 75-85 (1987).
- 10 By a group which can be converted *in vivo* into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol wherein the alcohol moiety is preferably a C₁₋₆-alkanol, a phenyl-C₁₋₃-alkanol, a C₃₋₉-cycloalkanol, while a C₅₋₈-cycloalkanol may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₅₋₈-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C₁₋₃-alkyl, phenyl-C₁₋₃-alkyl, phenyl-C₁₋₃-alkyloxycarbonyl or C₂₋₆-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₄₋₇-cycloalkenol, a C₃₋₅-alkenol, a phenyl-C₃₋₅-alkenol, a C₃₋₅-alkynol or phenyl-C₃₋₅-alkynol with the proviso that no bonds to the oxygen atom start from a
- 15 carbon atom which carries a double or triple bond, a C₃₋₈-cycloalkyl-C₁₋₃-alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms which may additionally be substituted in the bicycloalkyl moiety by one or two C₁₋₃-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula
- 20

25



wherein

- R_p denotes a C₁₋₈-alkyl, C₅₋₇-cycloalkyl, C₁₋₈-alkyloxy, C₅₋₇-cycloalkyloxy,
30 phenyl or phenyl-C₁₋₃-alkyl group,
- R_q denotes a hydrogen atom, a C₁₋₃-alkyl, C₅₋₇-cycloalkyl or phenyl group and
- R_r denotes a hydrogen atom or a C₁₋₃-alkyl group,

by a group which is negatively charged under physiological conditions is meant, for example, a tetrazol-5-yl, phenylcarbonylaminocarbonyl,

trifluoromethylcarbonylaminocarbonyl, C₁₋₆-alkylsulphonylamino,

- 5 phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C₁₋₆-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C₁₋₆-alkylsulphonylaminocarbonyl group

and by a group which can be cleaved *in vivo* from an imino or amino group is meant,

- 10 for example, a hydroxy group, an acyl group such as a phenylcarbonyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C₁₋₃-alkyl or C₁₋₃-alkyloxy groups, while the substituents may be identical or different, a pyridinoyl group or a C₁₋₁₆-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl
- 15 group, a C₁₋₁₆-alkyloxycarbonyl or C₁₋₁₆-alkylcarbonyloxy group, wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxy carbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl,
- 20 dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C₁₋₆-alkyloxycarbonyl
- 25 group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono- or disubstituted by C₁₋₆-alkyl or C₃₋₇-cycloalkyl groups and the substituents may be identical or different, a C₁₋₃-alkylsulphonyl-C₂₋₄-alkyloxycarbonyl, C₁₋₃-alkyloxy-C₂₋₄-alkyloxy-C₂₋₄-alkyloxycarbonyl, R_p-CO-O-(R_qCR_r)-O-CO, C₁₋₆-alkyl-
- 30 CO-NH-(R_sCR_t)-O-CO or C₁₋₆-alkyl-CO-O-(R_sCR_t)-(R_sCR_t)-O-CO group, wherein R_p to R_r are as hereinbefore defined,

R_s and R_t, which may be identical or different, denote hydrogen atoms or C₁₋₃-alkyl groups.

Moreover, the saturated alkyl and alkyloxy moieties which contain more than 2 carbon atoms mentioned in the foregoing definitions and those that follow, unless otherwise stated, also include the branched isomers thereof such as, for example,
5 the isopropyl, tert.butyl, isobutyl group, etc.

Preferred compounds of the above general formula I are those wherein

R¹ denotes a methyl group substituted by a group R_a, where

10

R_a denotes a 3,4-dihydro-quinolinyl group,

a 3,4-dihydro-isoquinolinyl group,

15

a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group,

a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group,

a 1*H*-benzo[*d*][1,2]oxazinyl or 1-oxo-1*H*-benzo[*d*][1,2]oxazinyl group,

20

a 4*H*-benzo[*e*][1,3]oxazinyl or 4-oxo-4*H*-benzo[*e*][1,3]oxazinyl group,

a 4*H*-benzo[*d*][1,3]oxazinyl or 4-oxo-4*H*-benzo[*d*][1,3]oxazinyl group,

25

a 2*H*-benzo[1,4]oxazinyl or 2-oxo-2*H*-benzo[1,4]oxazinyl group,

a 4*H*-benzo[*e*][1,3]thiazinyl or 4-oxo-4*H*-benzo[*e*][1,3]thiazinyl group,

a 4*H*-benzo[*d*][1,3]thiazinyl or 2*H*-benzo [1,4]thiazinyl group,

30

a 2-oxo-2*H*-benzo[*e*][1,3]oxazinyl or 2,2-dioxo-1*H*-benzo[*c*][1,2]thiazinyl group,

a 2,3-dihydro-1*H*-benzo[*e*][1,4]diazepinyl or 2-oxo-2,3-dihydro-1*H*-benzo[*e*][1,4]diazepinyl group,

- a 4,5-dihydro-3*H*-benzo[*b*][1,4]diazepinyl or 4-oxo-4,5-dihydro-3*H*-benzo[*b*][1,4]diazepinyl group,
- 5 a 5-oxo-4,5-dihydro-3*H*-benzo[*e*][1,4]diazepinyl group,
- a 2,3-dihydro-benzo[*f*][1,4]oxazepinyl or 2,3-dihydro-benzo[*b*][1,4]oxazepinyl group,
- 10 a 2,3-dihydro-benzo[*f*][1,4]thiazepinyl or 2,3-dihydro-benzo[*b*][1,4]thiazepinyl group,
- a 5-oxo-4,5-dihydro-benzo[*f*][1,3,4]oxadiazepinyl group,
- 15 a 11*H*-dibenzo[*b,e*]azepinyl or 11-oxo-11*H*-dibenzo[*b,e*]azepinyl group,
- a 11*H*-benzo[*e*]pyrido[3,2-*b*]azepinyl or a 5*H*-1,9,10-triaza-dibenzo[*a,d*]-cycloheptenyl group,
- 20 a 5*H*-dibenzo[*b,e*][1,4]diazepinyl or dibenzo[*b,f*][1,4]oxazepinyl group,
- a dibenzo[*b,f*][1,4]thiazepinyl, 5-oxo-dibenzo[*b,f*][1,4]thiazepinyl or 5,5-dioxo-dibenzo[*b,f*][1,4]thiazepinyl group,
- 25 a 5*H*-dibenzo[*a,d*]cycloheptenyl or 5*H*-dibenzo[*b,f*]azepinyl group,
- a phenanthridinyl, benzo[*c*][1,5]naphthyridinyl, benzo[*h*][1,6]naphthyridinyl, benzo[*c*][1,8]naphthyridinyl, benzo[*f*][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group,
- 30 a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenanthridinyl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphthyl or 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphthyl group,

20

a 2,3-dihydro-1*H*-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1*H*-4-oxa-10-aza-phenanthrenyl group,

5 a phenanthrenyl, benzo[*h*]quinolinyl, benzo[*f*]quinolinyl or benzo[*f*]quinoxalinyl group,

a 5*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepinyl, thieno[3,2-*b*][1,4]benzoxazepinyl, 5*H*-dibenzo[*d,f*][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[*a,c*]cycloheptenyl group,

10 a naphtho[1,2-*d*]oxazolyl, naphtho[2,1-*d*]oxazolyl, naphtho[1,2-*d*]thiazolyl, naphtho[2,1-*d*]thiazolyl, naphtho[1,2-*d*]imidazolyl, naphtho[1,2-*b*]furanyl or naphtho[2,1-*b*]furanyl group,

15 or a furo[3,2-*c*]isoquinolinyl, pyrazolo[1,5-*c*]quinazolinyl or 1*H*-perimidinyl group,

while the benzo groups of the above mentioned radicals R_a are substituted by the groups R¹⁰ to R¹³ and the alkylene units of the above mentioned groups R_a may be substituted by one or two fluorine atoms or one or two C₁₋₃-alkyl or

20 C₁₋₃-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals R_a may be substituted by a C₁₋₃-alkyl group and

R¹⁰ denotes a hydrogen atom,

25 a fluorine, chlorine, bromine or iodine atom,

a C₁₋₃-alkyl or cyclopropyl group,

a hydroxy, C₁₋₃-alkyloxy or cyclopropoxy group,

30 a nitro, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group,

a C₁₋₃-alkyl-carbonylamino or C₁₋₃-alkyl-sulphonylamino group,

- 21
- a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkyl-aminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group,
- 5 a mercapto, C₁₋₃-alkylsulphanyl, C₁₋₃-alkysulphinyl, C₁₋₃-alkylsulphonyl or aminosulphonyl group or
- 10 a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and
- R², R¹¹, R¹² and R¹³, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group,
- 15 R² denotes a hydrogen atom or
- a C₁₋₃-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group,
- Y denotes a nitrogen atom or a group of formula C-R⁵,
- 20 while R⁵ denotes a hydrogen atom or a C₁₋₃-alkyl group,
- R³ denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group,
- a 1-buten-1-yl group,
- 25 a 2-butyn-1-yl group or
- a 1-cyclopenten-1-ylmethyl group
- 30 and
- R⁴ denotes a (3-amino-piperidin-1-yl) group,

22

while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched,

the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts

5 thereof.

Particularly preferred are those compounds of the above general formula I wherein

10 R^1 denotes a methyl group substituted by a group R_a , where

R_a denotes a 3,4-dihydro-quinolin-2-yl group,

a 3,4-dihydro-isoquinolin-1-yl group,

15 a 1,4-dihydro-quinazolin-2-yl or 4-oxo-1,4-dihydro-quinazolin-2-yl group,

a 3,4-dihydro-quinazolin-2-yl or 4-oxo-3,4-dihydro-quinazolin-2-yl group,

20 a 1*H*-benzo[*d*][1,2]oxazin-4-yl or 1-oxo-1*H*-benzo[*d*][1,2]oxazin-4-yl group,

a 4*H*-benzo[*e*][1,3]oxazin-2-yl or 4-oxo-4*H*-benzo[*e*][1,3]oxazin-2-yl group,

a 4*H*-benzo[*d*][1,3]oxazin-2-yl or 4-oxo-4*H*-benzo[*d*][1,3]oxazin-2-yl group,

25 a 2*H*-benzo[1,4]oxazin-3-yl or 2-oxo-2*H*-benzo[1,4]oxazin-3-yl group,

a 4*H*-benzo[*e*][1,3]thiazin-2-yl or 4-oxo-4*H*-benzo[*e*][1,3]thiazin-2-yl group,

30 a 4*H*-benzo[*d*][1,3]thiazin-2-yl or 2*H*-benzo[1,4]thiazin-3-yl group,

a 2-oxo-2*H*-benzo[*e*][1,3]oxazin-4-yl or 2,2-dioxo-1*H*-benzo[*c*][1,2]thiazin-4-yl group,

- 23
- a 2,3-dihydro-1*H*-benzo[e][1,4]diazepin-5-yl or 2-oxo-2,3-dihydro-1*H*-benzo[e][1,4]diazepin-5-yl group,
- 5 a 4,5-dihydro-3*H*-benzo[b][1,4]diazepin-2-yl or 4-oxo-4,5-dihydro-3*H*-benzo[b][1,4]diazepin-2-yl group,
- a 5-oxo-4,5-dihydro-3*H*-benzo[e][1,4]diazepin-2-yl group,
- 10 a 2,3-dihydro-benzo[f][1,4]oxazepin-5-yl or 2,3-dihydro-benzo[b][1,4]oxazepin-4-yl group,
- a 2,3-dihydro-benzo[f][1,4]thiazepin-5-yl or 2,3-dihydro-benzo[b][1,4]thiazepin-4-yl group,
- 15 a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepin-2-yl group,
- a 11*H*-dibenzo[b,e]azepin-6-yl or 11-oxo-11*H*-dibenzo[b,e]azepin-6-yl group,
- 20 a 11*H*-benzo[e]pyrido[3,2-*b*]azepin-6-yl or a 5*H*-1,9,10-triaza-dibenzo[a,d]-cyclohepten-11-yl group,
- a 5*H*-dibenzo[b,e][1,4]diazepin-11-yl or dibenzo[b,f][1,4]oxazepin-11-yl group,
- 25 a dibenzo[b,f][1,4]thiazepin-11-yl, 5-oxo-dibenzo[b,f][1,4]thiazepin-11-yl or 5,5-dioxo-dibenzo[b,f][1,4]thiazepin-11-yl group,
- a 5*H*-dibenzo[a,d]cyclohepten-10-yl or 5*H*-dibenzo[b,f]azepin-10-yl group,
- 30 a phenanthridin-6-yl, benzo[c][1,5]naphthyridin-6-yl, benzo[h][1,6]naphthyridin-5-yl, benzo[c][1,8]naphthyridin-6-yl, benzo[f][1,7]naphthyridin-5-yl or 1,5,9-triaza-phenanthren-10-yl group,

- 24
- a 1,2,3,4-tetrahydro-phenanthridin-6-yl, 1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphth-5-yl or 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphth-5-yl group,
- 5 a 2,3-dihydro-1*H*-4-oxa-10-aza-phenanthren-9-yl or 1-oxo-2,3-dihydro-1*H*-4-oxa-10-aza-phenanthren-9-yl group,
- 10 a phenanthren-9-yl, benzo[*h*]quinolin-6-yl, benzo[*f*]quinolin-6-yl or benzo[*f*]quinoxalin-6-yl group,
- 15 a 5*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepin-11-yl, thieno[3,2-*b*][1,4]benzoxazepin-9-yl, 5*H*-dibenzo[*d,f*][1,3]diazepin-6-yl or 5-oxa-7-aza-dibenzo[*a,c*]cyclohepten-6-yl group,
- 20 a naphtho[1,2-*a*]oxazol-2-yl, naphtho[2,1-*d*]oxazol-2-yl, naphtho[1,2-*d*]thiazol-2-yl, naphtho[2,1-*d*]thiazol-2-yl, naphtho[1,2-*d*]imidazol-2-yl, naphtho[1,2-*b*]furan-2-yl or naphtho[2,1-*b*]furan-2-yl group,
- 25 while the benzo groups of the above mentioned radicals R_a are substituted by the groups R¹⁰ to R¹³ and the alkylene units of the above mentioned groups R_a may be substituted by one or two fluorine atoms or one or two methyl groups and the imino groups of the above mentioned radicals R_a may be substituted by a methyl group and
- R¹⁰ denotes a hydrogen atom,
- 30 a fluorine, chlorine, bromine or iodine atom,
- a methyl or ethyl group,
- a hydroxy, methoxy or ethoxy group or

25

a difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy group and

5 R^{11} , R^{12} and R^{13} , which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl, trifluoromethyl or methoxy group,

R^2 denotes a hydrogen atom or

10 a methyl, cyanomethyl, trifluoromethyl, ethyl, 2-cyano-ethyl, propyl, cyclopropyl or isopropyl group,

Y denotes a nitrogen atom or a group of formula $C-R^5$,

15 while R^5 denotes a hydrogen atom or a methyl, ethyl, propyl or isopropyl group,

R^3 denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group,

20 a 1-buten-1-yl group,

a 2-butyn-1-yl group or

25 a 1-cyclopenten-1-ylmethyl group

and

R^4 denotes a (3-amino-piperidin-1-yl) group,

30 the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

26

Most particularly preferred are those compounds of the above general formula I
wherein

R¹ denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group,

5

a dibenzo[b,f][1,4]oxazepin-11-ylmethyl group,

a phenanthridin-6-ylmethyl group,

10 a phenanthren-9-ylmethyl group or

a naphtho[1,2-d]oxazol-2-ylmethyl or naphtho[2,1-d]oxazol-2-ylmethyl group,

R² denotes a hydrogen atom or a methyl group,

15

Y denotes a nitrogen atom,

R³ denotes a 2-butyn-1-yl group

20 and

R⁴ denotes a (3-amino-piperidin-1-yl) group,


the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts

25 thereof.

27


The following compounds of general formula I deserve special mention:

- (1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




5

- (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




10

- (3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




- 15 (4) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




- 20 (5) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

28




(6) 2-((*S*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




5

(7) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



10


(8) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one



15

(9) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one

29



(10) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




5

the enantiomers, the mixtures thereof and the salts thereof.

10 According to the invention the compounds of general formula I are obtained by methods known *per se*, for example by the following methods:

a) deprotecting a compound of general formula

15



wherein R¹, R², Y and R³ are as hereinbefore defined and R^{4''} denotes one of the groups mentioned for R⁴ hereinbefore which contain an imino, 20 amino or alkylamino group, while the imino, amino or alkylamino group is substituted by a protective group.

The liberating of an amino group from a protected precursor is a standard reaction in synthetic organic chemistry. There are many examples of suitable protective groups.

30

A summary of the chemistry of protective groups can be found in Theodora W. Greene and Peter G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, published by John Wiley and Sons, and in Philip J. Kocienski, Protecting Groups, published by Georg Thieme, 1994.

5

The following are examples of protective groups:

the tert.-butyloxycarbonyl group which can be cleaved by treating with an acid such as for example trifluoroacetic acid or hydrochloric acid or by treating with

10 bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent such as methylene chloride, ethyl acetate, dioxane, methanol, isopropanol or diethylether at temperatures between 0°C and 80°C,

the 2,2,2-trichloroethoxycarbonyl group which can be cleaved by treating with metals such as for example zinc or cadmium in a solvent such as acetic acid or a mixture of tetrahydrofuran and a weak aqueous acid at temperatures between 0°C and the boiling temperature of the solvent used and

the carbobenzyloxycarbonyl group which can be cleaved for example by

20 hydrogenolysis in the presence of a noble metal catalyst such as for example palladium-charcoal and a solvent such as for example alcohols, ethyl acetate, dioxane, tetrahydrofuran or mixtures of these solvents at temperatures between 0°C and the boiling point of the solvent, by treating with boron tribromide in methylene chloride at temperatures between -20°C and ambient temperature, or by treating
25 with aluminium chloride/anisol at temperatures between 0°C and ambient temperature.

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example,

30 cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one stereocentre may be separated into their enantiomers.

Thus, for example, the cis/trans mixtures obtained may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general

31

formula I obtained which occur as racemates may be separated by methods known *per se* (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on

5 the basis of their physical-chemical differences using methods known *per se*, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

- 10 The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus
- 15 obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-O-p-toluoyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+)- or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (-)-menthyloxycarbonyl.
- 20

- Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts
- 25 with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
- 30 Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium

32

hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The compounds of general formula II used as starting materials are either known

- 5 from the literature or may be obtained by methods known from the literature (cf.
Examples I to XVI).

As already mentioned hereinbefore, the compounds of general formula I according to
the invention and the physiologically acceptable salts thereof have valuable

- 10 pharmacological properties, particularly an inhibiting effect on the enzyme DPP-IV.

The biological properties of the new compounds were investigated as follows:

The ability of the substances and their corresponding salts to inhibit the DPP-IV

- 15 activity can be demonstrated in a test set-up in which an extract of human colon
carcinoma cell line Caco-2 is used as the DPP IV source. The differentiation of the
cells in order to induce the DPP-IV expression was carried out as described by
Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco-2" ,
which appeared in Proc. Natl. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell
20 extract was obtained from cells solubilised in a buffer (10mM Tris HCl, 0.15 M NaCl,
0.04 t.i.u. aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifuging at 35,000 g for 30
minutes at 4°C (to remove cell debris).

The DPP-IV assay was carried out as follows:

- 25 50 µl substrate solution (AFC; AFC is amido-4-trifluoromethylcoumarin), final
concentration 100 µM, were placed in black microtitre plates. 20 µl of assay buffer
(final concentrations 50 mM Tris HCl pH 7.8, 50 mM NaCl, 1 % DMSO) was pipetted
in. The reaction was started by adding 30 µl of solubilised Caco-2 protein (final
30 concentration 0.14 µg of protein per well). The test substances to be investigated
were typically added prediluted in 20 µl, and the volume of assay buffer was then
reduced accordingly. The reaction was carried out at ambient temperature,
incubating for 60 minutes. Then the fluorescence was measured in a Victor 1420
Multilabel Counter, the excitation wavelength being 405 nm and the emission

33

wavelength being 535 nm. Blank readings (corresponding to 0 % activity) were obtained in mixtures without any Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100 % activity) were obtained in mixtures with no substance added. The potency of the test substances in question, expressed as IC₅₀ values, was calculated from dosage/activity curves consisting of 11 measuring points in each case. The following results were obtained:

Compound (Example No.)	DPP IV inhibition IC ₅₀ [nM]
1	14
1(1)	17
1(2)	58
1(3)	8
1(4)	9
1(7)	3
1(8)	7
1(9)	3

- 10 The compounds prepared according to the invention are well tolerated, as for example when 10 mg/kg of the compound of Example 1 were administered to rats by oral route no changes in the animals' behaviour could be detected.

In view of their ability to inhibit DPP-IV activity, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof are suitable for treating all those conditions or illnesses which can be influenced by the inhibition of the DPP-IV activity. It is therefore to be expected that the compounds according to the invention will be suitable for the prevention or treatment of diseases or conditions such as type I and type II diabetes mellitus, diabetic complications, metabolic acidosis or ketosis, insulin resistance, dyslipidaemias of various origins, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation and calcitonin-induced osteoporosis. In addition these substances are capable of preventing B-cell degeneration such as e.g. apoptosis or necrosis of pancreatic B-cells. The substances are also suitable for

34

improving or restoring the function of pancreatic cells and also increasing the number and size of pancreatic B-cells. Additionally, and on the basis of the role of the Glucagon-Like Peptides, such as e.g. GLP-1 and GLP-2 and their link with DPP-IV inhibition, it is likely that the compounds according to the invention are suitable for

- 5 achieving, *inter alia*, a sedative or anxiety-relieving effect and also of favourably affecting catabolic states after operations or hormonal stress responses or of reducing mortality or morbidity after myocardial infarct. They are also suitable for treating all conditions which are connected with the above mentioned effects and which are mediated by GLP-1 or GLP-2. The compounds according to the invention
10 may also be used as diuretics or antihypertensives and are suitable for preventing and treating acute renal failure. They are also suitable for the prevention and treatment of chronic inflammatory intestinal diseases. It is also expected that DPP-IV inhibitors and hence also the compounds according to the invention may be used to treat infertility or to improve fertility in humans or mammals, particularly when the
15 infertility is connected with insulin resistance or polycystic ovary syndrome. The substances are also suitable for treating deficiencies of growth hormone which are associated with reduced stature.

The compounds according to the invention may also be used in conjunction with

- 20 other active substances. Therapeutic agents which are suitable for such combinations include, for example, antidiabetics, such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinedione (e.g. rosiglitazone, pioglitazone), PPAR-gamma agonists (e.g. GI 262570), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), alpha2 antagonists, insulin
25 and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. Also, inhibitors of protein tyrosine phosphatase 1, substances which influence deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen
30 synthase kinase or pyruvate dehydrokinase, lipid lowering agents, such as HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and its derivatives, cholesterol absorption inhibitors such as for example ezetimibe, bile acid-binding substances such as for example cholestyramine, HDL-raising compounds such as for example inhibitors of CETP or

35

regulators of ABC1 or active substances for the treatment of obesity, such as e.g. sibutramine or tetrahydrolipostatin, or β_3 -agonists such as SB-418790 or AD-9677.

It is also possible to combine the compounds with drugs for treating high blood

- 5 pressure such as e.g. AII antagonists or ACE inhibitors, diuretics, β -blockers, etc., or combinations thereof.

The dosage required to achieve such an effect is expediently, by intravenous route, 1

to 100 mg, preferably 1 to 30 mg, and by oral route 1 to 1000 mg, preferably 1 to 100

- 10 mg, in each case 1 to 4 times a day. For this purpose, the compounds of formula I

prepared according to the invention, optionally combined with other active

substances, may be incorporated together with one or more inert conventional

carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline

cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water,

- 15 water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene

glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard

fat or suitable mixtures thereof into conventional galenic preparations such as plain

or coated tablets, capsules, powders, suspensions or suppositories.

20

The Examples that follow are intended to illustrate the invention:

Preparation of the starting compounds:

Example I2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]-5 oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one317 mg 11-chloromethyl-dibenzo[*b,f*][1,4]oxazepin are added to 400 mg 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one and 276 mg potassium carbonate in 4 ml N,N-dimethylformamide.

The reaction mixture is stirred for two hours at 80°C. For working up it is combined

10 with water and the precipitate formed is suction filtered. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.

Yield: 120 mg (20 % of theory)

Mass spectrum (ESI⁺): m/z = 594 [M+H]⁺

15

The following compounds are obtained analogously to Example I:

(1) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

20

(2) 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

25

(3) 2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneR_f value: 0.41 (silica gel, cyclohexane/ethyl acetate = 3:7)Mass spectrum (ESI⁺): m/z = 592 [M+H]⁺

30

(4) 2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneR_f value: 0.50 (silica gel, cyclohexane/ethyl acetate = 2:8)Mass spectrum (ESI⁺): m/z = 608 [M+H]⁺

37

(5) 2-bromo-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

Mass spectrum (ESI⁺): m/z = 474, 476 [M+H]⁺

5 (6) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[2,1-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

R_f value: 0.80 (silica gel, methylene chloride/ethanol = 9:1)

10 (7) 2-bromo-3-(2-butyn-1-yl)-5-[(naphtho[1,2-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

R_f value: 0.50 (silica gel, methylene chloride/methanol = 19:1)

(8) 2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-cyano-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

15 R_f value: 0.40 (silica gel, petroleum ether/ethyl acetate = 1:4)

Mass spectrum (ESI⁺): m/z = 426 [M+H]⁺

Example II

2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

2.50 g 3-(tert.-butyloxycarbonylamino)-piperidine are added to 2.65 g 2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one and 2.12 g sodium carbonate in 5 ml dimethylsulphoxide. The reaction mixture is stirred overnight at 85°C.

After cooling to ambient temperature it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium carbonate and evaporated down. The crude product is further reacted without any further purification.

Mass spectrum (ESI⁺): m/z = 387 [M+H]⁺

30 The following compounds are obtained analogously to Example II:

(1) 2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

R_f value: 0.15 (silica gel, cyclohexane/ethyl acetate = 3:7)

38

Mass spectrum (ESI⁺): m/z = 401 [M+H]⁺(2) 2-[*(S)*-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one5 Mass spectrum (ESI⁺): m/z = 594 [M+H]⁺(3) 2-[*(R)*-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneMass spectrum (ESI⁺): m/z = 594 [M+H]⁺

10

(4) 2-[*(R)*-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(naphtho[2,1-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneR_f value: 0.70 (silica gel, methylene chloride/ethanol = 9:1)

15

(5) 2-[*(R)*-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(naphtho[1,2-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneR_f value: 0.65 (silica gel, methylene chloride/methanol = 9:1)Mass spectrum (ESI⁺): m/z = 568 [M+H]⁺

20

(6) 2-[*(R)*-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-oneMass spectrum (ESI⁺): m/z = 387 [M+H]⁺R_f value: 0.50 (silica gel, methylene chloride/ethanol = 9:1)

25

Example III2-bromo-3-(2-butyn-1-yl)-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one0.63 ml hydrazine hydrate are added dropwise to 3.68 g methyl 2-bromo-3-(2-butyn-1-yl)-5-formyl-3*H*-imidazole-4-carboxylate in 50 ml of ethanol. The reaction mixture is stirred for one hour at ambient temperature, then 3 ml acetic acid are added and the

30

reaction mixture is refluxed for a further hour. The precipitate formed is suction filtered, washed with ethanol and diethyl ether and dried.

Yield: 2.65 g (77 % of theory)

Mass spectrum (ESI⁺): m/z = 267, 269 [M+H]⁺

Example IVmethyl 2-bromo-3-(2-butyn-1-yl)-5-formyl-3*H*-imidazole-4-carboxylate

45 ml diisobutylaluminium hydride solution (1M in toluene) are added dropwise to 12.45 g dimethyl 2-bromo-3-(2-butyn-1-yl)-1*H*-imidazole-4,5-dicarboxylate in 150 ml of tetrahydrofuran under an argon atmosphere at -65°C. The reaction mixture is stirred for two hours at -65°C, then another 9 ml diisobutylaluminium hydride solution are added. After another hour the reaction mixture is quenched at -65°C with a mixture of 1 M hydrochloric acid and tetrahydrofuran (1:1) and stirred for ten minutes.

Then the cooling bath is removed, the reaction mixture is diluted with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (2:1 to 1:1).

Yield: 9.58 g (85 % of theory)

Mass spectrum (ESI⁺): m/z = 285, 287 [M+H]⁺

15

The following compounds are obtained analogously to Example IV:

(1) methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3*H*-imidazole-4-carboxylate

Mass spectrum (ESI⁺): m/z = 301, 303 [M+H]⁺

20

Example Vdimethyl 2-bromo-3-(2-butyn-1-yl)-1*H*-imidazole-4,5-dicarboxylate

4.53 ml of 1-bromo-2-butyne are added to 13.20 g dimethyl 2-bromo-1*H*-imidazole-4,5-dicarboxylate and 8.57 g potassium carbonate in 70 ml N,N-dimethylformamide and the reaction mixture is stirred overnight at ambient temperature.

For working up it is combined with water and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.

Yield: 14.58 g (92 % of theory)

Mass spectrum (ESI⁺): m/z = 315, 317 [M+H]⁺

30

The following compounds are obtained analogously to Example V:

(1) dimethyl 2-bromo-3-(3-methyl-2-buten-1-yl)-1*H*-imidazole-4,5-dicarboxylate

Mass spectrum (ESI⁺): m/z = 331, 333 [M+H]⁺

Example VIDimethyl 2-bromo-1*H*-imidazole-4,5-dicarboxylate

6.11 ml bromine are added to 19.80 g dimethyl 1*H*-imidazole-4,5-dicarboxylate and 5 14.92 g potassium carbonate in 600 ml methylene chloride. The reaction mixture is stirred for one hour at ambient temperature, then a mixture of saturated sodium sulphite solution and saturated sodium chloride solution (1:1) is added. The organic phase is largely separated off and the aqueous phase is extracted with ethyl acetate several times. The combined organic phases are dried over magnesium sulphate 10 and evaporated down, leaving about 7.40 g crude product. The aqueous phase is combined with ethyl acetate and extracted overnight in an extraction apparatus. The ethyl acetate extract is evaporated down and the flask residue is combined with the crude product already obtained.

Yield: 13.10 g (46 % of theory)

15 Mass spectrum (ESI⁺): m/z = 263, 265 [M+H]⁺

Example VII2-Bromo-3-(2-butyn-1-yl)-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

0.50 ml of 1-bromo-2-butyne are added to 1.30 g 2-bromo-7-methyl-3,5-dihydro-20 imidazo[4,5-*d*]pyridazin-4-one and 0.99 ml Hünig base in 30 ml of N,N-dimethylformamide. The reaction mixture is stirred for three hours at ambient temperature. Then the solvent is distilled off *in vacuo* using the rotary evaporator. The flask residue is stirred with 40 ml of water and 0.5 ml concentrated aqueous ammonia solution, suction filtered and washed with ethanol as well as diethyl ether.

25 Yield: 1.30 g (82 % of theory)

R_f value: 0.60 (silica gel, cyclohexane/ethyl acetate = 3:7)

Mass spectrum (ESI⁺): m/z = 281, 283 [M+H]⁺

Example VIII2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one

5.20 ml of a 1.8 M solution of bromine in acetonitrile are slowly added dropwise to 1.40 g of 7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 1.30 g potassium carbonate in 40 ml acetonitrile. Then the reaction mixture is heated to 70°C, whereupon the mixture is rapidly decolourised. More bromine solution and potassium carbonate are added batchwise until the reaction has ended, according to HPLC-MS. For working up the reaction mixture is evaporated down, stirred with 100 ml of water and suction filtered. The filtrate is acidified with 1 M hydrochloric acid and extracted 10 with ethyl acetate. The combined extracts are dried over sodium sulphate and evaporated down.

Yield: 1.30 g (61 % of theory)

R_f value: 0.37 (silica gel, methylene chloride/methanol = 9:1)

Mass spectrum (ESI⁺): m/z = 229, 231 [M+H]⁺

15

Example IX7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one

A solution of 4.00 g sodium nitrite in 15 ml of water is added dropwise at 50°C to 2.20 g of 4-amino-7-methyl-3*H*-imidazo[4,5-d]pyridazine in a mixture of 30 ml acetic acid, 5 ml of water and 0.5 ml concentrated sulphuric acid. The reaction mixture is stirred for a further two hours at 50°C and then heated to 90°C for one hour. After cooling to ambient temperature the reaction mixture is diluted with 30 ml of water. The precipitate formed is suction filtered, washed with water, ethanol and diethyl ether and dried.

25 Yield: 1.00 g (45 % of theory)

Mass spectrum (ESI⁺): m/z = 151 [M+H]⁺

Example X4-amino-7-methyl-3*H*-imidazo[4,5-d]pyridazine

30 A mixture of 2.00 g 5-acetyl-3*H*-imidazole-4-carbonitrile and 4.00 ml hydrazine hydrate in 50 ml of ethanol is heated to 100 °C, until the reaction is complete according to HPLC-MS. After cooling to ambient temperature the reaction mixture is evaporated down, stirred with 20 ml of cold ethanol and suction filtered. The filter cake is washed with diethyl ether and dried.

42

Yield: 2.10 g (95 % of theory)

Mass spectrum (ESI⁺): m/z = 150 [M+H]⁺Example XI5 5-acetyl-3*H*-imidazole-4-carbonitrile

57 ml of a 3 M solution of methylmagnesium bromide in diethyl ether are added to 7.00 g of 4,5-dicyano-imidazole in 80 ml of tetrahydrofuran under an argon atmosphere, while the temperature is maintained between 5°C and 15°C.

After two hours the reaction is complete according to thin layer chromatography and 10 the reaction mixture is diluted with 400 ml of ethyl acetate. Then 400 ml saturated ammonium chloride solution are slowly added. After ten minutes the mixture is acidified with semiconcentrated sulphuric acid and stirred for another twenty minutes before the organic phase is separated off. The aqueous phase is extracted with ethyl acetate and the combined organic phases are dried over sodium sulphate and 15 evaporated down. The flask residue is stirred with ethyl acetate, suction filtered and washed with ethyl acetate and diethyl ether.

Yield: 3.30 g (43 % of theory)

Mass spectrum (ESI⁺): m/z = 136 [M+H]⁺20 Example XII2-chloromethyl-naphtho[2,1-*d*]oxazole

Prepared by reacting 2.93 g of 2-amino-1-naphthol with 3.54 g of 2-chloro-1,1,1-triethoxy-ethane in 25 ml of ethanol at 60°C.

Yield: 1.90 g (58 % of theory)

25 R_f value: 0.55 (silica gel, petroleum ether/ethyl acetate = 9:1)Mass spectrum (ESI⁺): m/z = 218, 220 [M+H]⁺

The following compounds are obtained analogously to Example XII:

30 (1) 2-chloromethyl-naphtho[1,2-*d*]oxazoleR_f value: 0.90 (silica gel, methylene chloride/methanol = 19:1)Mass spectrum (ESI⁺): m/z = 218, 220 [M+H]⁺

43

Example XIII2-bromo-3-(3-methyl-2-buten-1-yl)-3,5-dihydro-imidazo[4,5-c]pyridin-4-one

1.55 g Burgess reagent (methoxycarbonylsulphamoyl-triethylammonium-N-betaine)

are added to 1.60 g of 2-bromo-7-hydroxy-3-(3-methyl-2-buten-1-yl)-3,5,6,7-

5 tetrahydro-imidazo[4,5-c]pyridin-4-one in 20 ml methylene chloride and 4 ml of tetrahydrofuran. The reaction mixture is stirred for eight hours at 60°C, then another 0.3 equivalents Burgess reagent is added. After a further two hours the cooled reaction mixture is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are dried over

10 magnesium sulphate and evaporated down. The flask residue is chromatographed through a silica gel column with methylene chloride/methanol (1:0 to 10:1) as eluant.

Yield: 1.06 g (60 % of theory)

Mass spectrum (ESI⁺): m/z = 282, 284 [M+H]⁺15 Example XIV2-bromo-7-hydroxy-3-(3-methyl-2-buten-1-yl)-3,5,6,7-tetrahydro-imidazo[4,5-c]pyridin-4-one

90 ml of water and 5.40 g iron powder are added to 4.15 g methyl 2-bromo-5-(1-hydroxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate in 270 ml

20 of ethanol. The mixture is refluxed, combined with 36 ml glacial acetic acid and stirred for one and a half hours at reflux temperature. The cooled reaction solution is filtered through Celite. The filtrate is evaporated down, combined with ethanol and made basic with solid potassium carbonate. The mixture is stirred for three hours at 60°C. Then the ethanol is distilled off, the flask residue is combined with water and

25 extracted with ethyl acetate. The combined extracts are dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (1:1 to 7:1) as eluant.

Yield: 1.62 g (47 % of theory)

Mass spectrum (ESI⁺): m/z = 300, 302 [M+H]⁺

30

Example XV

Methyl 2-bromo-5-(1-hydroxy-2-nitro-ethyl)-3-(3-methyl-2-buten-1-yl)-3*H*-imidazole-4-carboxylate

35 ml nitromethane are added to 1.14 g caesium carbonate in 15 ml of methanol at 5 ambient temperature. Then the mixture is combined with a solution of 3.50 g methyl 2-bromo-3-(3-methyl-2-buten-1-yl)-5-formyl-3*H*-imidazole-4-carboxylate in 20 ml of methanol and 5 ml methylene chloride and stirred for 15 minutes at ambient temperature. Then 0.5 ml acetic acid are added and the solution is evaporated down *in vacuo*. The flask residue is combined with aqueous sodium hydrogen carbonate 10 solution and extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down.

Yield: 4.15 g (99 % of theory)

Mass spectrum (ESI⁺): m/z = 362, 364 [M+H]⁺

15 Example XVI

2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one


40 mg sodium methoxide (95 %) are added to a solution of 605 mg 2-[(*R*)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-cyanomethyl-3,5-dihydro-20 imidazo[4,5-*d*]pyridazin-4-one in 9 ml of methanol. The mixture is stirred for one hour at ambient temperature and then neutralised with 41 µL glacial acetic acid. Then a solution of 195 mg anthranilic acid in 2 ml of methanol is added and the reaction mixture is heated to 70°C. After about two hours a white, voluminous precipitate is formed and the reaction mixture is cooled to ambient temperature. The precipitate 25 formed is suction filtered, washed with cold methanol and dried.

Yield: 234 mg (30 % of theory)

Mass spectrum (ESI⁺): m/z = 545 [M+H]⁺

45

Preparation of the final compounds:

Example 1

- 5 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-
3,5-dihydro-imidazo[4,5-d]pyridazin-4-one

0.33 ml trifluoroacetic acid are added to 120 mg 2-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one in 3 ml methylene chloride while cooling with an ice bath. The reaction mixture is stirred overnight at ambient temperature.


10 For working up it is poured onto cooled saturated potassium carbonate solution and extracted with methylene chloride. The organic phase is separated off and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (100:0 to 70:30) as eluant.

15 Yield: 63 mg (63 % of theory)

Mass spectrum (ESI⁺): m/z = 494 [M+H]⁺

The following compounds are obtained analogously to Example 1:

- 20 (1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one




Mass spectrum (ESI⁺): m/z = 478 [M+H]⁺

Boehringer Ingelheim International GmbH
55216 Ingelheim

Case 1/1502
foreign filing text


46
(2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



Mass spectrum (ESI⁺): m/z = 477 [M+H]⁺

5

(3) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one x trifluoroacetic acid




R_f value: 0.45 (Reversed phase ready-made TLC plate (E. Merck), acetonitrile/water/

10 trifluoroacetic acid = 50:50:0.1)

Mass spectrum (ESI⁺): m/z = 492 [M+H]⁺

(4) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




15

Carried out with isopropanolic hydrochloric acid (5-6 M) in methylene chloride.

Mass spectrum (ESI⁺): m/z = 508 [M+H]⁺


- 47
- (5) 2-((S)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



Mass spectrum (ESI⁺): m/z = 494 [M+H]⁺

5


- (6) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



Mass spectrum (ESI⁺): m/z = 494 [M+H]⁺

10

- (7) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




R_f value: 0.40 (silica gel, methylene chloride/ethanol/conc. aqueous ammonia =

15 90:10:2)

Mass spectrum (ESI⁺): m/z = 468 [M+H]⁺

- (8) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



20

48

Mass spectrum (ESI⁺): m/z = 468 [M+H]⁺(9) 2-((R)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one

5

Mass spectrum (ESI⁺): m/z = 445 [M+H]⁺

The following compounds may also be obtained analogously to the foregoing

10 Examples and other methods known from the literature:

No.	Name	Structural formula
(1)	2-(3-amino-piperidin-1-yl)-3-(2-buten-1-yl)-5-[(3,4-dihydro-quinolin-2-yl)methyl]-6,7-dimethyl-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(2)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3,4-dihydro-isoquinolin-1-yl)methyl]-7-cyclopropyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(3)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3,3-dimethyl-3,4-dihydro-isoquinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(4)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4,4-dimethyl-3,4-dihydro-isoquinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

49

(5)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-methyl-1,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(6)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-methyl-4-oxo-1,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(7)	2-(3-amino-piperidin-1-yl)-3-(2-buten-1-yl)-5-[(5,6,7,8-tetrafluoro-1-methyl-1,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(8)	2-(3-amino-piperidin-1-yl)-3-(2-buten-1-yl)-5-[(3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(9)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(10)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3-methyl-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(11)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(1 <i>H</i> -benzo[<i>d</i>][1,2]oxazin-4-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(12)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-oxo-1 <i>H</i> -benzo[<i>d</i>][1,2]oxazin-4-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

50

(13)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4H-benzo[e][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(14)	2-(3-amino-piperidin-1-yl)-3-(2-buten-1-yl)-5-[(4,4-dimethyl-4H-benzo[e][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(15)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-4H-benzo[e][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(16)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4H-benzo[d][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(17)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4H-benzo[d][1,3]oxazin-2-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(19)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4,4-dimethyl-4H-benzo[d][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(20)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(21)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2H-benzo[1,4]oxazin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	

51

(22)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2-oxo-2H-benzo[1,4]oxazin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(23)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,2-dimethyl-2H-benzo[1,4]oxazin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(24)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[4H-benzo[e][1,3]thiazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(25)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[4,4-dimethyl-4H-benzo[e][1,3]thiazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(26)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[4-oxo-4H-benzo[e][1,3]thiazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(27)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4H-benzo[d][1,3]thiazin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(28)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2H-benzo[1,4]thiazin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(29)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2-oxo-2H-benzo[e][1,3]oxazin-4-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	

52

(30)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-methyl-2,2-dioxo-1H-benzo[c][1,2]thiazin-4-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(31)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(32)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(33)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(34)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(35)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(36)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-methyl-4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	







53

(37)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(38)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[4-methyl-5-oxo-4,5-dihydro-3H-benzo[e][1,4]diazepin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(39)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-benzo[f][1,4]oxazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(40)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3,3-dimethyl-2,3-dihydro-benzo[f][1,4]oxazepin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(41)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,2-dimethyl-2,3-dihydro-benzo[f][1,4]oxazepin-5-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(42)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-benzo[b][1,4]oxazepin-4-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(43)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(6,6-dimethyl-2,3-dihydro-benzo[b][1,4]oxazepin-4-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	

54

(44)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-benzo[b][1,4]thiazepin-4-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(45)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,2-dimethyl-2,3-dihydro-benzo[b][1,4]thiazepin-4-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(46)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-benzo[f][1,4]thiazepin-5-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(47)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepin-2-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(48)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(11H-dibenzo[b,e]azepin-6-yl)methyl]-7-ethyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(49)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(11H-dibenzo[b,e]azepin-6-yl)methyl]-7-cyanomethyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(50)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(11,11-difluoro-11H-dibenzo[b,e]azepin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	







55

(51)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(11-oxo-11H-dibenzo[b,e]azepin-6-yl)methyl]-7-(2-cyanoethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(52)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(11H-benzo[e]pyrido[3,2-b]azepin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(53)	2-(3-amino-piperidin-1-yl)-(2-butyn-1-yl)-5-[(5H-1,9,10-triaza-dibenzo[a,d]cyclohepten-11-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(54)	2-(3-amino-piperidin-1-yl)-3-(2-butene-1-yl)-5-[(5-methyl-5H-dibenzo[b,e][1,4]-diazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(55)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(dibenzo[b,f][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(56)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[b,f][1,4]thiazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	

56

(57)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(dibenzo[<i>b,f</i>][1,4]thiazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(58)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-oxo-dibenzo[<i>b,f</i>][1,4]thiazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(59)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5,5-dioxo-dibenzo[<i>b,f</i>][1,4]-thiazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(60)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5 <i>H</i> -dibenzo[<i>a,d</i>]cyclohepten-10-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(61)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-methyl-5 <i>H</i> -dibenzo[<i>b,f</i>]azepin-10-yl)methyl]-7-trifluoromethyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(62)	2-(3-amino-piperidin-1-yl)-3-(3-methyl-2-buten-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

57

(63)	2-(3-amino-piperidin-1-yl)-3-(2-buten-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(64)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(65)	2-(3-amino-piperidin-1-yl)-3-[(1-cyclopenten-1-yl)methyl]-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(66)	2-(3-amino-piperidin-1-yl)-3-(1-buten-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(67)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[c][1,5]naphthyridin-6-yl)methyl]-7-cyclopropyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(68)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[h][1,6]naphthyridin-5-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

58

(69)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[c][1,8]naphthyridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(70)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-benzo[f][1,7]naphthyridin-5-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(71)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1,5,9-triaza-phenanthren-10-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(72)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1,2,3,4-tetrahydrophenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(73)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(74)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-1H-4-aza-cyclopenta[a]naphth-5-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(75)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(8,9,10,11-tetrahydro-7H-6-aza-cyclohepta[a]naphth-5-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	

59

(76)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2,3-dihydro-1 <i>H</i> -4-oxa-10-aza-phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(77)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1-oxo-2,3-dihydro-1 <i>H</i> -4-oxa-10-aza-phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(78)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(10-cyanophenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(79)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[<i>h</i>]quinolin-6-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(80)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[<i>f</i>]quinolin-6-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(81)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(benzo[<i>f</i>]quinoxalin-6-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(82)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5 <i>H</i> -benzo[e]pyrrolo[1,2-a][1,4]diazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

60

(83)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(thieno[3,2-b][1,4]benzoxazepin-9-yl)methyl]-7-trifluoromethyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(84)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(thieno[3,2-b][1,4]benzoxazepin-9-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(85)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5H-dibenzo[d,f][1,3]diazepin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(86)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(5-methyl-5H-dibenzo[d,f][1,3]diazepin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(87)	2-(3-amino-piperidin-1-yl)-3-(3-methylbut-2-en-1-yl)-5-[(5-oxa-7-aza-dibenzo[a,c]cyclohepten-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-c]pyridin-4-one	
(88)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-d]thiazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	
(89)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-d]thiazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one	

61

(90)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(3H-naphtho[1,2- <i>a</i>]imidazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(91)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2- <i>b</i>]furan-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(92)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1- <i>b</i>]furan-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(93)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(2-methyl-furo[3,2- <i>c</i>]isoquinolin-5-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>c</i>]pyridin-4-one	
(94)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(pyrazolo[1,5- <i>c</i>]quinazolin-5-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	
(95)	2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(1 <i>H</i> -perimidin-2-yl)methyl]-3,5-dihydro-imidazo[4,5- <i>d</i>]pyridazin-4-one	

Example 25 Coated tablets containing 75 mg of active substance

1 tablet core contains:

active substance	75.0 mg
calcium phosphate	93.0 mg
10 corn starch	35.5 mg
polyvinylpyrrolidone	10.0 mg
hydroxypropylmethylcellulose	15.0 mg
magnesium stearate	<u>1.5 mg</u>
	230.0 mg

15

Preparation:

The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of

20 magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape.

25 Weight of core: 230 mg

die: 9 mm, convex

The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.

30 Weight of coated tablet: 245 mg.

Example 3Tablets containing 100 mg of active substance

5 Composition:

1 tablet contains:

active substance	100.0 mg
lactose	80.0 mg
corn starch	34.0 mg
10 polyvinylpyrrolidone	4.0 mg
magnesium stearate	<u>2.0 mg</u>
	220.0 mg

Method of Preparation:

15 The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.

20 Weight of tablet: 220 mg

Diameter: 10 mm, biplanar, faceted on both sides and notched on one side.

Example 4Tablets containing 150 mg of active substance

25

Composition:

1 tablet contains:

active substance	150.0 mg
powdered lactose	89.0 mg
30 corn starch	40.0 mg
colloidal silica	10.0 mg
polyvinylpyrrolidone	10.0 mg
magnesium stearate	<u>1.0 mg</u>
	300.0 mg

Preparation:

The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.

Weight of tablet: 300 mg

die: 10 mm, flat

10

Example 5Hard gelatine capsules containing 150 mg of active substance

15 1 capsule contains:

active substance	150.0 mg
corn starch (dried)	approx. 80.0 mg
lactose (powdered)	approx. 87.0 mg
magnesium stearate	<hr/> 3.0 mg
	approx. 420.0 mg

20

Preparation:

The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The 25 finished mixture is packed into size 1 hard gelatine capsules.

Capsule filling: approx. 320 mg

Capsule shell: size 1 hard gelatine capsule.

Example 6Suppositories containing 150 mg of active substance

1 suppository contains:

5	active substance	150.0 mg
	polyethyleneglycol 1500	550.0 mg
	polyethyleneglycol 6000	460.0 mg
	polyoxyethylene sorbitan monostearate	<u>840.0 mg</u>
		2,000.0 mg

10

Preparation:

After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.

15 Example 7Suspension containing 50 mg of active substance

100 ml of suspension contain:

	active substance	1.00 g
20	carboxymethylcellulose-Na-salt	0.10 g
	methyl p-hydroxybenzoate	0.05 g
	propyl p-hydroxybenzoate	0.01 g
	glucose	10.00 g
	glycerol	5.00 g
25	70% sorbitol solution	20.00 g
	flavouring	0.30 g
	dist. water	ad
		100 ml

Preparation:

30 The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the

66

sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.

5 ml of suspension contain 50 mg of active substance.

5 Example 8

Ampoules containing 10 mg active substance

Composition:

active substance	10.0 mg		
0.01 N hydrochloric acid q.s.			
double-distilled water	ad	2.0 ml	

Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

Example 9

Ampoules containing 50 mg of active substance

20 Composition:


active substance	50.0 mg		
0.01 N hydrochloric acid q.s.			
double-distilled water	ad	10.0 ml	

25 Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

Patent Claims

5 1. Compounds of general formula



wherein

10

R^1 denotes a C_{1-3} -alkyl group substituted by a group R_a , where

15

R_a denotes a 3,4-dihydro-quinolinyl, 3,4-dihydro-isoquinolinyl, 1,4-dihydro-quinazolinyl, 3,4-dihydro-quinazolinyl, 1*H*-benzo[*d*][1,2]oxazinyl, 4*H*-benzo[*e*][1,3]oxazinyl, 4*H*-benzo[*d*][1,3]oxazinyl or 2*H*-benzo[1,4]oxazinyl group, wherein in each case

20

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group,

a 4*H*-benzo[*e*][1,3]thiazinyl, 4*H*-benzo[*d*][1,3]thiazinyl or 2*H*-benzo [1,4]thiazinyl group wherein in each case

25

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group,

68

a 2-oxo-2*H*-benzo[e][1,3]oxazinyl or 2,2-dioxo-1*H*-benzo[c][1,2]thiazinyl group
wherein in each case in the benzo moiety

one to three methyne groups may each be replaced by a nitrogen atom,

5

a 2,3-dihydro-1*H*-benzo[e][1,4]diazepinyl, 4,5-dihydro-3*H*-benzo[b][1,4]diazepinyl or 5-oxo-4,5-dihydro-3*H*-benzo[e][1,4]diazepinyl group wherein in each case

10 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group,

15 a 2,3-dihydro-benzo[f][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group wherein in each case

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group,

20

a 2,3-dihydro-benzo[b][1,4]thiazepinyl or 2,3-dihydro-benzo[f][1,4]thiazepinyl group wherein in each case

25 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and in the heterocycll moiety a methylene group may be replaced by a carbonyl group and the sulphur atom may be replaced by a sulphinyl or sulphonyl group,

a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepinyl group wherein

30

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom,

69

a 11*H*-dibenzo[*b,e*]azepinyl or 5*H*-dibenzo[*a,d*]cycloheptenyl group wherein in each case

5 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and the methylene group in the heterocycll moiety may be replaced by an oxygen or sulphur atom, a carbonyl, sulphinyl or sulphonyl group or by an imino group substituted by R_x, where

10 R_x denotes a hydrogen atom or a C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkynyl, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₃-alkyl, aryl, aryl-C₁₋₃-alkyl, hydroxy-C₂₋₄-alkyl, C₁₋₃-alkyloxy-C₂₋₄-alkyl, C₃₋₆-cycloalkyloxy-C₂₋₄-alkyl, amino-C₂₋₄-alkyl, C₁₋₃-alkylamino-C₂₋₄-alkyl, di-(C₁₋₃-alkyl)-amino-C₂₋₄-alkyl, C₁₋₃-alkyl-carbonyl, C₁₋₃-alkyloxy-carbonyl, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyl, aryl-carbonyl, 15 C₁₋₃-alkyl-sulphonyl or aryl-sulphonyl group,

a phenanthridinyl group wherein

20 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom, and

25 a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenanthridinyl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphthyl or a 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphthyl group wherein in each case

30 in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom and one or two methylene groups may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, the oxygen atoms must be separated from one another by at least two methylene units,

a phenanthrenyl group wherein

70

in each case one to three of the methyne groups in position 1 to 4 and 5 to 8 may each be replaced by a nitrogen atom,

a 1,2,3,4-tetrahydro-phenanthrenyl or a 1,2,3,4,5,6,7,8-octahydro-

5 phenanthrenyl group wherein

in each case one or two of the methylene groups in position 1 to 4 and 5 to 8 may each be replaced by an oxygen atom or a carbonyl group, while, if two methylene groups are each replaced by an oxygen atom, 10 the oxygen atoms must be separated from one another by at least two methylene units,

a 5*H*-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl, thieno[3,2-b][1,4]benzoxazepinyl, 5*H*-dibenzo[d,f][1,3]diazepinyl or a 5-oxa-7-aza-dibenzo[a,c]cycloheptenyl

15 group wherein in each case

in the benzo moiety one to three methyne groups may each be replaced by a nitrogen atom,

20 a naphtho[1,2-*d*]oxazolyl, naphtho[2,1-*d*]oxazolyl , naphtho[1,2-*d*]thiazolyl, naphtho[2,1-*d*]thiazolyl, naphtho[1,2-*d*]imidazolyl, naphtho[1,2-*b*]furanyl or naphtho[2,1-*b*]furanyl group wherein in each case

25 in the naphthyl moiety one to three methyne groups may each be replaced by a nitrogen atom,

or a furo[3,2-c]isoquinolinyl, pyrazolo[1,5-c]quinazolinyl or 1*H*-perimidinyl group,

30 while the methylene and methyne groups of the above mentioned radicals R_a may be substituted by the groups R¹⁰ to R¹³ and additionally by a C₁₋₃-alkyl group and the imino groups of the above mentioned radicals R_a may be substituted by the groups R_x as hereinbefore defined and

71

R¹⁰ denotes a hydrogen atom,

a fluorine, chlorine, bromine or iodine atom.

5 a C₁₋₄-alkyl, hydroxy, or C₁₋₄-alkyloxy group,

a nitro, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)amino, cyano-C₁₋₃-alkylamino, N-(cyano-C₁₋₃-alkyl)-N-(C₁₋₃-alkyl)-amino, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, 10 piperazin-1-yl, or 4-(C₁₋₃-alkyl)-piperazin-1-yl group,

a C₁₋₃-alkyl-carbonylamino, arylcarbonylamino, aryl-C₁₋₃-alkyl-carbonylamino, C₁₋₃-alkyloxy-carbonylamino, aminocarbonylamino, C₁₋₃-alkylaminocarbonylamino, di-(C₁₋₃-alkyl)aminocarbonylamino, pyrrolidin-1-yl-carbonylamino, piperidin-1-yl-carbonylamino, morpholin-4-yl-carbonylamino, piperazin-1-yl-carbonylamino or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonylamino, C₁₋₃-alkyl-sulphonylamino, bis-(C₁₋₃-alkylsulphonyl)-amino, aminosulphonylamino, C₁₋₃-alkylamino-sulphonylamino, di-(C₁₋₃-alkyl)amino-sulphonylamino, pyrrolidin-1-yl-sulphonylamino, piperidin-1-yl-sulphonylamino, morpholin-4-yl-sulphonylamino, piperazin-1-yl-sulphonylamino or 4-(C₁₋₃-alkyl)-piperazin-1-yl-sulphonylamino, (C₁₋₃-alkylamino)thiocarbonylamino, (C₁₋₃-alkyloxy-carbonyl-amino)carbonylamino, arylsulphonylamino or aryl-C₁₋₃-alkyl-sulphonyl-amino group,

25 an N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-arylcarbonyl-amino, N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyloxy-carbonylamino, N-(aminocarbonyl)-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl-aminocarbonyl)-C₁₋₃-alkylamino, N-[di-(C₁₋₃-alkyl)aminocarbonyl]-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-sulphonylamino, N-(C₁₋₃-alkyl)-arylsulphonylamino, or N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-sulphonylamino group,

72

a 2-oxo-imidazolidin-1-yl, 2,4-dioxo-imidazolidin-1-yl, 2,5-dioxo-imidazolidin-1-yl or 2-oxo-hexahydropyrimidin-1-yl group wherein the nitrogen atom in the 3 position may be substituted in each case by a methyl or ethyl group,

5

a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkyl-aminocarbonyl, di-(C₁₋₃-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl group,

10

a C₁₋₃-alkyl-carbonyl or an arylcarbonyl group,

15

a carboxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyl, cyano-C₁₋₃-alkyl, aminocarbonyl-C₁₋₃-alkyl, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyl, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyl, piperidin-1-yl-carbonyl-C₁₋₃-alkyl, morpholin-4-yl-carbonyl-C₁₋₃-alkyl, piperazin-1-yl-carbonyl-C₁₋₃-alkyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyl group,

20

a carboxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyloxy, cyano-C₁₋₃-alkyloxy, aminocarbonyl-C₁₋₃-alkyloxy, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyloxy, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyloxy, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyloxy, piperidin-1-yl-carbonyl-C₁₋₃-alkyloxy, morpholin-4-yl-carbonyl-C₁₋₃-alkyloxy, piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy group,

25

a hydroxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl, pyrrolidin-1-yl-C₁₋₃-alkyl, piperidin-1-yl-C₁₋₃-alkyl, morpholin-4-yl-C₁₋₃-alkyl, piperazin-1-yl-C₁₋₃-alkyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyl group,

30

a hydroxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphanyl-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphinyl-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphonyl-C₁₋₃-alkyloxy, amino-C₁₋₃-alkyloxy, C₁₋₃-alkylamino-C₁₋₃-alkyloxy, di-(C₁₋₃-

73

alkyl)-amino-C₁₋₃-alkyloxy, pyrrolidin-1-yl-C₁₋₃-alkyloxy, piperidin-1-yl-C₁₋₃-alkyloxy, morpholin-4-yl-C₁₋₃-alkyloxy, piperazin-1-yl-C₁₋₃-alkyloxy or 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyloxy group,

5 a mercapto, C₁₋₃-alkylsulphanyl, C₁₋₃-alkysulphinyl, C₁₋₃-alkylsulphonyl, C₁₋₃-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphanyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group,

10 a sulpho, aminosulphonyl, C₁₋₃-alkyl-aminosulphonyl, di-(C₁₋₃-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-sulphonyl group,

15 a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,

a C₂₋₄-alkenyl or C₂₋₄-alkynyl group,

20 a C₃₋₄-alkenyloxy or C₃₋₄-alkynyoxy group,

a C₃₋₆-cycloalkyl or C₃₋₆-cycloalkyloxy group,

25 a C₃₋₆-cycloalkyl-C₁₋₃-alkyl or C₃₋₆-cycloalkyl-C₁₋₃-alkyloxy group or
an aryl, aryloxy, aryl-C₁₋₃-alkyl or aryl-C₁₋₃-alkyloxy group,

30 R¹¹ and R¹², which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, a C₁₋₃-alkyl, trifluoromethyl, hydroxy, C₁₋₃-alkyloxy or cyano group, or

R¹¹ together with R¹², if these are bound to adjacent carbon atoms, also denotes a methylenedioxy, difluoromethylenedioxy, ethylenedioxy or a straight-chain C₃₋₅-alkylene group and

R^{13} denotes a hydrogen atom, a fluorine, chlorine or bromine atom, a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkyloxy group,

5 R^2 denotes a hydrogen, fluorine or chlorine atom,

a C_{1-6} -alkyl group,

a C_{2-4} -alkenyl group,

10 a C_{3-4} -alkynyl group,

a C_{3-6} -cycloalkyl group,

15 a C_{3-6} -cycloalkyl- C_{1-3} -alkyl group,

a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranyl methyl or tetrahydropyranyl methyl group,

20 an aryl group,

an aryl- C_{1-4} -alkyl group,

an aryl- C_{2-3} -alkenyl group,

25 an arylcarbonyl group,

an arylcarbonyl- C_{1-2} -alkyl group,

30 a heteroaryl group,

an heteroaryl- C_{1-3} -alkyl group,

a furanylcarbonyl, thienylcarbonyl, thiazolylcarbonyl or pyridylcarbonyl group,

a furanylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group,

5 a C₁₋₄-alkyl-carbonyl group,

a C₁₋₄-alkyl-carbonyl-C₁₋₂-alkyl group,

a C₃₋₆-cycloalkyl-carbonyl group,

10 a C₃₋₆-cycloalkyl-carbonyl-C₁₋₂-alkyl group,

an aryl-A or aryl-A-C₁₋₃-alkyl group, where A denotes an oxygen or sulphur atom, an imino, C₁₋₃-alkylimino, sulphinyl or sulphonyl group,

15 a group R_b, where

R_b denotes a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkylamino-carbonyl, di-(C₁₋₃-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, 20 piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-ethylpiperazin-1-ylcarbonyl, hydroxy, mercapto, C₁₋₃-alkyloxy, C₁₋₃-alkylsulphenyl, C₁₋₃-alkylsulphinyl, C₁₋₃-alkylsulphonyl, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, pyrrolidin-1-yl, 25 piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group,

or a C₁₋₄-alkyl group substituted by a group R_b, where R_b is as hereinbefore defined,

Y denotes a nitrogen atom or a group of formula C-R⁵,

30 while R⁵ is defined like R² and in each case one of the two groups R² and R⁵ must be a hydrogen atom or a C₁₋₃-alkyl group,

R³ denotes a C₃₋₈-alkyl group,

a C₁₋₃-alkyl group substituted by a group R_c, where

R_c denotes a C₃₋₇-cycloalkyl group optionally substituted by one or two C₁₋₃-alkyl groups,

a C₅₋₇-cycloalkenyl group optionally substituted by one or two C₁₋₃-alkyl groups,

10 an aryl group or

a furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl group, while the above mentioned heterocyclic groups may each be substituted by one or two C₁₋₃-alkyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, cyano or C₁₋₃-alkyloxy group,

a C₃₋₈-alkenyl group,

20 a C₃₋₆-alkenyl group substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl group,

a C₃₋₈-alkynyl group,

25 an aryl group or

an aryl-C₂₋₄-alkenyl group,

and

30

R⁴ denotes an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C₁₋₃-alkylamino or a di-(C₁₋₃-alkyl)amino group and may additionally be substituted by one or two C₁₋₃-alkyl groups,

77

a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position or in the 4 position by an amino, C₁₋₃-alkylamino or a di-(C₁₋₃-alkyl)amino group and may additionally be substituted by one or two C₁₋₃-alkyl groups,

- 5 a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl-moiety is additionally substituted by an aminocarbonyl, C₁₋₂-alkyl-aminocarbonyl, di-(C₁₋₂-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl-)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group,
- 10 a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl moiety in the 4 position or in the 5 position is additionally substituted by a hydroxy or methoxy group,
- 15 a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group,
- 20 a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino- group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl-group are replaced by a straight-chain alkylene bridge, this bridge containing 2 to 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or 1 to 4 carbon atoms, if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms, if the hydrogen atoms are located on carbon atoms which are separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms,
- 25 an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl group,
- 30 a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C₁₋₃-alkyl groups,

78

a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted at the carbon skeleton by one or two C₁₋₃-alkyl groups,

a [1,4]diazepan-1-yl group optionally substituted by one or two C₁₋₃-alkyl groups,

5 which is substituted in the 6 position by an amino group,

a C₃₋₇-cycloalkyl group which is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

10 a C₃₋₇-cycloalkyl group which is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

15 a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an

20 amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms,

an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two

25 nitrogen atoms at the cycloalkyl moiety are separated from one another by at least two carbon atoms,

a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

30 an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

79

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl

5 moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

10

an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

15 a R¹⁹-C₂₋₄-alkylamino group wherein R¹⁹ is separated from the nitrogen atom of the C₂₋₄-alkylamino moiety by at least two carbon atoms and

R¹⁹ denotes an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

20 an R¹⁹-C₂₋₄-alkylamino group wherein the nitrogen atom of the C₂₋₄-alkylamino moiety is substituted by a C₁₋₃-alkyl group and R¹⁹ is separated from the nitrogen atom of the C₂₋₄-alkylamino moiety by at least two carbon atoms, while R¹⁹ is as hereinbefore defined,

25 an amino group substituted by the group R²⁰ wherein

R²⁰ denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-ylmethyl group, while the groups mentioned for R²⁰ may each be substituted by one or two C₁₋₃-alkyl groups,

30

80

an amino group substituted by the group R²⁰ and a C₁₋₃-alkyl group wherein R²⁰ is as hereinbefore defined, while the groups mentioned for R²⁰ may each be substituted by one or two C₁₋₃-alkyl groups,

- 5 an R¹⁹-C₃₋₄-alkyl group wherein the C₃₋₄-alkyl moiety is straight-chained and may additionally be substituted by one or two C₁₋₃-alkyl groups, while R¹⁹ is as hereinbefore defined,

a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group,

- 10 a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group,

- 15 or an azetidin-2-yl-C₁₋₂-alkyl, azetidin-3-yl-C₁₋₂-alkyl, pyrrolidin-2-yl-C₁₋₂-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C₁₋₂-alkyl, piperidin-2-yl-C₁₋₂-alkyl, piperidin-3-yl, piperidin-3-yl-C₁₋₂-alkyl, piperidin-4-yl or piperidin-4-yl-C₁₋₂-alkyl group, while the above mentioned groups may each be substituted by one or two C₁₋₃-alkyl groups,

- 20 while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be mono- or disubstituted by R_h, while the substituents may be identical or different and R_h denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C₁₋₃-alkyl,
25 cyclopropyl, ethenyl, ethynyl, hydroxy, C₁₋₃-alkyloxy, difluoromethoxy or trifluoromethoxy group,

- 30 by the heteroaryl groups mentioned in the definition of the above groups are meant a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group,

or a pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two methyne groups are replaced by nitrogen atoms,

81

or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group,
wherein one to three methyne groups are replaced by nitrogen atoms,

and the above mentioned heteroaryl groups may be mono- or disubstituted by
5 R_h , while the substituents may be identical or different and R_h is as
hereinbefore defined,

while, unless otherwise stated, the above mentioned alkyl, alkenyl and alkynyl groups
may be straight-chain or branched,

10 and the hydrogen atoms of the methyl or ethyl groups contained in the definitions
may be wholly or partly replaced by fluorine atoms,

15 the tautomers, enantiomers, diastereomers, the mixtures thereof, the prodrugs
thereof and the salts thereof.

2. Compounds of general formula I according to claim 1, wherein

20 R^1 denotes a methyl group substituted by a group R_a , where

R_a denotes a 3,4-dihydro-quinolinyl group,

a 3,4-dihydro-isoquinolinyl group,

25 a 1,4-dihydro-quinazolinyl or 4-oxo-1,4-dihydro-quinazolinyl group,

a 3,4-dihydro-quinazolinyl or 4-oxo-3,4-dihydro-quinazolinyl group,

30 a 1*H*-benzo[*d*][1,2]oxazinyl or 1-oxo-1*H*-benzo[*d*][1,2]oxazinyl group,

a 4*H*-benzo[*e*][1,3]oxazinyl or 4-oxo-4*H*-benzo[*e*][1,3]oxazinyl group,

a 4*H*-benzo[*d*][1,3]oxazinyl or 4-oxo-4*H*-benzo[*d*][1,3]oxazinyl group,

a 2*H*-benzo[1,4]oxazinyl or 2-oxo-2*H*-benzo[1,4]oxazinyl group,

5 a 4*H*-benzo[e][1,3]thiazinyl or 4-oxo-4*H*-benzo[e][1,3]thiazinyl group,

a 4*H*-benzo[d][1,3]thiazinyl or 2*H*-benzo [1,4]thiazinyl group,

10 a 2-oxo-2*H*-benzo[e][1,3]oxazinyl or 2,2-dioxo-1*H*-benzo[c][1,2]thiazinyl group,

a 2,3-dihydro-1*H*-benzo[e][1,4]diazepinyl or 2-oxo-2,3-dihydro-1*H*-benzo[e][1,4]diazepinyl group,

15 a 4,5-dihydro-3*H*-benzo[b][1,4]diazepinyl or 4-oxo-4,5-dihydro-3*H*-benzo[b][1,4]diazepinyl group,

20 a 2,3-dihydro-benzo[f][1,4]oxazepinyl or 2,3-dihydro-benzo[b][1,4]oxazepinyl group,

a 2,3-dihydro-benzo[f][1,4]thiazepinyl or 2,3-dihydro-benzo[b][1,4]thiazepinyl group,

25 a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepinyl group,

a 11*H*-dibenzo[b,e]azepinyl or 11-oxo-11*H*-dibenzo[b,e]azepinyl group,

30 a 11*H*-benzo[e]pyrido[3,2-*b*]azepinyl or a 5*H*-1,9,10-triaza-dibenzo[a,d]-cycloheptenyl group,

a 5*H*-dibenzo[b,e][1,4]diazepinyl or dibenzo[b,f][1,4]oxazepinyl group,

a dibenzo[b,f][1,4]thiazepinyl, 5-oxo-dibenzo[b,f][1,4]thiazepinyl or 5,5-dioxo-dibenzo[b,f][1,4]thiazepinyl group,

a 5*H*-dibenzo[*a,d*]cycloheptenyl or 5*H*-dibenzo[*b,f*]azepinyl group,

a phenanthridinyl, benzo[*c*][1,5]naphthyridinyl, benzo[*h*][1,6]naphthyridinyl,

5 benzo[*c*][1,8]naphthyridinyl, benzo[*f*][1,7]naphthyridinyl or 1,5,9-triaza-phenanthrenyl group,

10 a 1,2,3,4-tetrahydro-phenanthridinyl, 1,2,3,4,4a,10b-hexahydro-phenanthridinyl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphthyl or 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphthyl group,

15 a 2,3-dihydro-1*H*-4-oxa-10-aza-phenanthrenyl or 1-oxo-2,3-dihydro-1*H*-4-oxa-10-aza-phenanthrenyl group,

20 a phenanthrenyl, benzo[*h*]quinolinyl, benzo[*f*]quinolinyl or benzo[*f*]quinoxalinyl group,

25 a 5*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepinyl, thieno[3,2-*b*][1,4]benzoxazepinyl, 5*H*-dibenzo[*d,f*][1,3]diazepinyl or 5-oxa-7-aza-dibenzo[*a,c*]cycloheptenyl group,

30 a naphtho[1,2-*d*]oxazolyl, naphtho[2,1-*d*]oxazolyl , naphtho[1,2-*d*]thiazolyl, naphtho[2,1-*d*]thiazolyl, naphtho[1,2-*d*]imidazolyl, naphtho[1,2-*b*]furanyl or naphtho[2,1-*b*]furanyl group,

35 or a furo[3,2-*c*]isoquinolinyl, pyrazolo[1,5-*c*]quinazolinyl or 1*H*-perimidinyl group,

40 while the benzo groups of the above mentioned radicals R_a are substituted by the groups R¹⁰ to R¹³ and the alkylene units of the above mentioned groups R_a may be substituted by one or two fluorine atoms or one or two C₁₋₃-alkyl or C₁₋₃-alkyloxy-carbonyl groups and the imino groups of the above mentioned radicals R_a may be substituted by a C₁₋₃-alkyl group and

R¹⁰ denotes a hydrogen atom,

- a fluorine, chlorine, bromine or iodine atom,
- 5 a C₁₋₃-alkyl or cyclopropyl group,
- a hydroxy, C₁₋₃-alkyloxy or cyclopropoxy group,
- a nitro, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group,
- 10 a C₁₋₃-alkyl-carbonylamino or C₁₋₃-alkyl-sulphonylamino group,
- a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkyl-aminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group,
- 15 a mercapto, C₁₋₃-alkylsulphanyl, C₁₋₃-alkysulphinyl, C₁₋₃-alkylsulphonyl or aminosulphonyl group or
- a difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy group and
- 20 R¹¹, R¹² and R¹³, which may be identical or different, in each case represent a hydrogen atom, a fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or methoxy group,
- 25 R² denotes a hydrogen atom or
- a C₁₋₃-alkyl, cyclopropyl, trifluoromethyl, cyanomethyl or 2-cyano-ethyl group,
- Y denotes a nitrogen atom or a group of formula C-R⁵,
- 30 while R⁵ denotes a hydrogen atom or a C₁₋₃-alkyl group,
- R³ denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group,

85

a 1-buten-1-yl group,

a 2-butyn-1-yl group or

5 a 1-cyclopenten-1-ylmethyl group

and

R⁴ denotes a (3-amino-piperidin-1-yl) group,

10

while, unless otherwise stated, the above mentioned alkyl groups may be straight-chain or branched,

the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts

15 thereof.

3. Compounds of general formula I according to claim 2, wherein

20 R¹ denotes a methyl group substituted by a group R_a, where

R_a denotes a 3,4-dihydro-quinolin-2-yl group,

a 3,4-dihydro-isoquinolin-1-yl group,

25

a 1,4-dihydro-quinazolin-2-yl or 4-oxo-1,4-dihydro-quinazolin-2-yl group,

a 3,4-dihydro-quinazolin-2-yl or 4-oxo-3,4-dihydro-quinazolin-2-yl group,

30

a 1*H*-benzo[*d*][1,2]oxazin-4-yl or 1-oxo-1*H*-benzo[*d*][1,2]oxazin-4-yl group,

a 4*H*-benzo[*e*][1,3]oxazin-2-yl or 4-oxo-4*H*-benzo[*e*][1,3]oxazin-2-yl group,

a 4*H*-benzo[*d*][1,3]oxazin-2-yl or 4-oxo-4*H*-benzo[*d*][1,3]oxazin-2-yl group,

- a 2*H*-benzo[1,4]oxazin-3-yl or 2-oxo-2*H*-benzo[1,4]oxazin-3-yl group,
- 5 a 4*H*-benzo[e][1,3]thiazin-2-yl or 4-oxo-4*H*-benzo[e][1,3]thiazin-2-yl group,
- 10 a 4*H*-benzo[d][1,3]thiazin-2-yl or 2*H*-benzo[1,4]thiazin-3-yl group,
- 15 a 2-oxo-2*H*-benzo[e][1,3]oxazin-4-yl or 2,2-dioxo-1*H*-benzo[c][1,2]thiazin-4-yl group,
- 20 a 2,3-dihydro-1*H*-benzo[e][1,4]diazepin-5-yl or 2-oxo-2,3-dihydro-1*H*-benzo[e][1,4]diazepin-5-yl group,
- 25 a 4,5-dihydro-3*H*-benzo[b][1,4]diazepin-2-yl or 4-oxo-4,5-dihydro-3*H*-benzo[b][1,4]diazepin-2-yl group,
- 30 a 5-oxo-4,5-dihydro-3*H*-benzo[e][1,4]diazepin-2-yl group,
- a 2,3-dihydro-benzo[f][1,4]oxazepin-5-yl or 2,3-dihydro-benzo[b][1,4]oxazepin-4-yl group,
- a 2,3-dihydro-benzo[f][1,4]thiazepin-5-yl or 2,3-dihydro-benzo[b][1,4]thiazepin-4-yl group,
- 35 a 5-oxo-4,5-dihydro-benzo[f][1,3,4]oxadiazepin-2-yl group,
- a 11*H*-dibenzo[b,e]azepin-6-yl or 11-oxo-11*H*-dibenzo[b,e]azepin-6-yl group,
- a 11*H*-benzo[e]pyrido[3,2-*b*]azepin-6-yl or a 5*H*-1,9,10-triaza-dibenzo[a,d]-cyclohepten-11-yl group,
- 40 a 5*H*-dibenzo[b,e][1,4]diazepin-11-yl or dibenzo[b,f][1,4]oxazepin-11-yl group,

- 87
- a dibenzo[*b,f*][1,4]thiazepin-11-yl, 5-oxo-dibenzo[*b,f*][1,4]thiazepin-11-yl or 5,5-dioxo-dibenzo[*b,f*][1,4]thiazepin-11-yl group,
- 5 a 5H-dibenzo[*a,d*]cyclohepten-10-yl or 5*H*-dibenzo[*b,f*]azepin-10-yl group,
- 10 a phenanthridin-6-yl, benzo[*c*][1,5]naphthyridin-6-yl, benzo[*h*][1,6]naphthyridin-5-yl, benzo[*c*][1,8]naphthyridin-6-yl, benzo[*f*][1,7]naphthyridin-5-yl or 1,5,9-triaza-phenanthren-10-yl group,
- 15 a 1,2,3,4-tetrahydro-phenanthridin-6-yl, 1,2,3,4,4a,10*b*-hexahydro-phenanthridin-6-yl, 2,3-dihydro-1*H*-4-aza-cyclopenta[*a*]naphth-5-yl or 8,9,10,11-tetrahydro-7*H*-6-aza-cyclohepta[*a*]naphth-5-yl group,
- 20 a 2,3-dihydro-1*H*-4-oxa-10-aza-phenanthren-9-yl or 1-oxo-2,3-dihydro-1*H*-4-oxa-10-aza-phenanthren-9-yl group,
- 25 a phenanthren-9-yl, benzo[*h*]quinolin-6-yl, benzo[*f*]quinolin-6-yl or benzo[*f*]quinoxalin-6-yl group,
- 30 a 5*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepin-11-yl, thieno[3,2-*b*][1,4]benzoxazepin-9-yl, 5*H*-dibenzo[*d,f*][1,3]diazepin-6-yl or 5-oxa-7-aza-dibenzo[*a,c*]cyclohepten-6-yl group,
- a naphtho[1,2-*d*]oxazol-2-yl, naphtho[2,1-*d*]oxazol-2-yl, naphtho[1,2-*d*]thiazol-2-yl, naphtho[2,1-*d*]thiazol-2-yl, naphtho[1,2-*d*]imidazol-2-yl, naphtho[1,2-*b*]furan-2-yl or naphtho[2,1-*b*]furan-2-yl group,
- or a furo[3,2-*c*]isoquinolin-5-yl, pyrazolo[1,5-*c*]quinazolin-5-yl or 1*H*-perimidin-2-yl group,
- while the benzo groups of the above mentioned radicals R_a are substituted by the groups R¹⁰ to R¹³ and the alkylene units of the above mentioned groups R_a may be substituted by one or two fluorine atoms or one or two methyl groups

Boehringer Ingelheim International GmbH
55216 Ingelheim

Case 1/1502
foreign filing text

88

and the imino groups of the above mentioned radicals R_a may be substituted by a methyl group and

R¹⁰ denotes a hydrogen atom,

5

a fluorine, chlorine, bromine or iodine atom,

a methyl or ethyl group,

10

a hydroxy, methoxy or ethoxy group or

a difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy group and

15

R¹¹, R¹² and R¹³, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom or a methyl, trifluoromethyl or methoxy group,

R² denotes a hydrogen atom or

20

a methyl, cyanomethyl, trifluoromethyl, ethyl, 2-cyano-ethyl, propyl, cyclopropyl or isopropyl group,

Y denotes a nitrogen atom or a group of formula C-R⁵,

25

while R⁵ denotes a hydrogen atom or a methyl, ethyl, propyl or isopropyl group,

R³ denotes a 2-buten-1-yl or 3-methyl-2-buten-1-yl group,

30

a 1-buten-1-yl group,

a 2-butyn-1-yl group or

89

a 1-cyclopenten-1-ylmethyl group

and

5 R⁴ denotes a (3-amino-piperidin-1-yl) group,

the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

10

4. Compounds of general formula I according to claim 1, wherein

R¹ denotes a 4-oxo-3,4-dihydro-quinazolin-2-ylmethyl group,

15 a dibenzo[b,f][1,4]oxazepin-11-ylmethyl group,

a phenanthridin-6-ylmethyl group,

a phenanthren-9-ylmethyl group or

20

a naphtho[1,2-d]oxazol-2-ylmethyl or naphtho[2,1-d]oxazol-2-ylmethyl group,

R² denotes a hydrogen atom or a methyl group,

25 Y denotes a nitrogen atom,

R³ denotes a 2-butyn-1-yl group

and


30

R⁴ denotes a (3-amino-piperidin-1-yl) group,


the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof.

5. The following compounds of general formula I according to claim 1:


- 5 (1) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



- 10 (2) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




- (3) 2-(3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthren-9-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




15

- (4) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(phenanthridin-6-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




20


- 91
- (5) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-7-methyl-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




- 5 (6) 2-((*S*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



- 10 (7) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(dibenzo[*b,f*][1,4]oxazepin-11-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




- (8) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[2,1-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one




15

- (9) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(naphtho[1,2-*d*]oxazol-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*d*]pyridazin-4-one



(10) 2-((*R*)-3-amino-piperidin-1-yl)-3-(2-butyn-1-yl)-5-[(4-oxo-3,4-dihydro-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-*a*]pyridazin-4-one



the enantiomers, the mixtures thereof and the salts thereof.

6. Physiologically acceptable salts of the compounds according to claims 1 to 5 with

10 inorganic or organic acids.

7. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5 or a salt according to claim 6 optionally together with one or more inert carriers and/or diluents.

15

8. Use of a compound according to at least one of claims 1 to 5 or a salt according to claim 6 for preparing a pharmaceutical composition which is suitable for the treatment of type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis caused by calcitonin.

20

9. Process for preparing a pharmaceutical composition according to claim 7, characterised in that a compound according to at least one of claims 1 to 5 or a salt according to claim 6 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.


25

93

10. Process for preparing the compounds of general formula I according to claims 1 to 6, characterised in that

a) a compound of general formula

5



wherein R¹, R², Y and R³ are as hereinbefore defined and

10 R^{4''} denotes one of the groups mentioned for R⁴ hereinbefore which contain an imino, amino or alkylamino group, where the imino, amino or alkylamino group is substituted by a protective group, is deprotected and

subsequently, if desired, a protective group used during the reactions to protect

15 reactive groups is cleaved, and/or

a compound of general formula I thus obtained is resolved into its stereoisomers and/or

20 a compound of general formula I thus obtained is converted into its salts, particularly for pharmaceutical use into the physiologically acceptable salts thereof with an inorganic or organic acid.

Fetherstonhaugh
Ottawa, Canada
Patent Agents